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Asbestos is still a serious problem all around the world, even 
though the devastating health effects of breathing in the 
microscopically tiny mineral fibres have been known for over a 
century. Asbestos exposure causes a variety of severe pulmonary 
diseases and unfortunately due to the long latency period 
between exposure and development of disease, this epidemic will 
continue, even in countries where asbestos use has been banned 
for many years.
Asbestos-related lung cancer is one of the most common types 
of occupational cancer. It is clinically indistinguishable from lung 
cancer in patients with no known history of asbestos exposure 
and the treatment is the same for both etiologic types. Never-
theless, the molecular basis may be different and diagnosis as 
well as prognosis and treatment strategies may benefit from the 
identification of specific asbestos-related molecular alterations. In 
addition, these kinds of molecular correlates could be of impor-
tance in resolving some of the medico-legal issues arising from 
occupational diseases.
This study sheds light on the molecular alterations related to 
asbestos exposure in lung cancer and may point the way for the 
development of molecular-based clinical methods for asbestos-
related lung cancer. 
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Background
Asbestos is a well known cancer-causing mineral fi bre, which has a syn-
ergistic effect on lung cancer risk in combination with tobacco smoking. 
Several in vitro and in vivo experiments have demonstrated that asbestos 
can evoke chromosomal damage and cause alterations as well as gene 
expression changes. Lung tumours, in general, have very complex karyo-
types with several recurrently gained and lost chromosomal regions and 
this has made it diffi cult to identify specifi c molecular changes related 
primarily to asbestos exposure. The main aim of  these studies has been 
to characterize asbestos-related lung cancer at a molecular level. 
Methods
Samples from asbestos-exposed and non-exposed lung cancer patients 
were studied using array comparative genomic hybridization (aCGH) and 
fl uorescent in situ hybridization (FISH) to detect copy number altera-
tions (CNA) as well as microsatellite analysis to detect allelic imbalance 
(AI). In addition, asbestos-exposed cell lines were studied using gene 
expression microarrays. 
Results
Eighteen chromosomal regions showing differential copy number in 
the lung tumours of  asbestos-exposed patients compared to those of  
non-exposed patients were identifi ed. The most signifi cant differences 
were detected at 2p21–p16.3, 5q35.3, 9q33.3–q34.11, 9q34.13–q34.3, 
11p15.5, 14q11.2 and 19p13.1–p13.3 (p<0.005). The alterations at 2p 
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and 9q were validated and characterized in detail using AI and FISH 
analysis in a larger study population. Furthermore, in vitro studies were 
performed to examine the early gene expression changes induced by 
asbestos in three different lung cell lines. The results revealed specifi c 
asbestos-associated gene expression profi les and biological processes as 
well as chromosomal regions enriched with genes believed to contribute 
to the common asbestos-related responses in the cell lines. Interestingly, 
the most signifi cant region enriched with asbestos-response genes was 
identifi ed at 2p22, close to the previously identifi ed region showing 
asbestos-related CNA in lung tumours. Additionally, in this thesis, the 
dysregulated biological processes (Gene Ontology terms) detected in the 
cell line experiment were compared to dysregulated processes identifi ed 
in patient samples in a later study (Ruosaari et al., 2008a). Commonly 
affected processes such as those related to protein ubiquitination, ion 
transport and surprisingly sensory perception of  smell were identifi ed. 
Conclusions
The identifi cation of  specifi c CNAs and dysregulated biological pro-
cesses shed some light on the underlying genes acting as mediators in 
asbestos-related lung carcinogenesis. It is postulated that the combina-
tion of  several asbestos-specifi c molecular alterations could be used to 
develop a diagnostic method for the identifi cation of  asbestos-related 
lung cancer.
13
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Tausta
Asbesti on tunnettu syöpää aiheuttava mineraalikuitu, jolla on tupa-
koinnin yhteydessä synergistinen vaikutus keuhkosyövän riskiin. Useat 
in vitro- ja in vivo -tutkimukset ovat osoittaneet, että asbesti voi aiheuttaa 
kromosomivaurioita ja muutoksia geenien ilmentymisessä. Keuhkosyö-
vän karyotyyppi on yleensä hyvin monimutkainen ja toistuvat kromo-
somialueiden monistumat sekä häviämät ovat yleisiä. Tästä syystä on 
ollut vaikeaa tunnistaa spesifi siä molekyylitason muutoksia, jotka liittyvät 
pääasiassa asbestialtistumiseen. Päätavoite näissä tutkimuksissa on ollut 
asbestiin liittyvän keuhkosyövän tunnistaminen molekyylitasolla. 
Menetelmät
Asbestialtistuneiden ja altistumattomien keuhkosyöpäpotilaiden näytteet 
tutkittiin käyttäen vertailevaa genomista hybridisaatiota mikrosiruilla 
(aCGH) ja fl uoresenssi in situ hybridisaatiota (FISH), joilla havaitaan 
kromosomialueiden kopiolukumuutokset, sekä mikrosatelliittianalyysia, 
jolla havaitaan alleeliepätasapaino (AI). Lisäksi asbestialtistuneita solu-
linjoja tutkittiin käyttäen geeniekspressiomikrosiruja. 
Tulokset
Kahdeksallatoista kromosomialueella osoitettiin kopiolukueroja as-
bestialtistuneiden ja altistumattomien potilaiden näytteiden välillä. 
Merkittävimmät erot havaittiin kromosomialueilla 2p21–p16.3, 5q35.3, 
9q33.3–q34.11, 9q34.13–q34.3, 11p15.5, 14q11.2 ja 19p13.1–p13.3 
14
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(p <0,005). Muutokset 2p ja 9q alueilla karakterisoitiin tarkemmin ja var-
mennettiin käyttäen AI- ja FISH-analyysejä laajemmassa tutkimusaineis-
tossa. Lisäksi mikrosiruilla tutkittiin muutokset geenien ilmentymisessä 
asbestialtistuksen jälkeen kolmessa eri keuhkosolulinjassa. Tutkimuksessa 
tunnistettiin asbestialtistukseen liittyviä geenien ilmentymisprofi ileja 
sekä muuttuneita biologisia prosesseja. Lisäksi havaittiin solulinjoille 
yhteisten asbestiin liittyvien vastegeenien rikastuttamia kromosomaali-
sia alueita. Merkittävin asbestivastegeenejä sisältävä alue oli 2p22, joka 
sijaitsee lähellä aiemmin keuhkosyövissä tunnistettua asbestiin liittyviä 
kopiolukumuutoksia sisältävää aluetta 2p:ssa. Tässä väitöskirjassa ver-
tailtiin myös asbestialtistuneiden solulinjojen muuttuneita biologisia 
prosesseja (geeniontologiatermejä) niihin muuttuneisiin prosesseihin, 
joita myöhemmin havaittiin asbestialtistuneiden potilaiden näytteissä 
(Ruosaari et al., 2008a). Yhteiset muuttuneet prosessit liittyivät proteii-
nien ubikitinaatioon, ionikuljetukseen ja yllättävästi hajuaistimukseen. 
Johtopäätökset
Spesifi sten kopiolukumuutosten ja muuttuneiden biologisten prosessien 
tunnistaminen asbestiin liittyvässä keuhkosyövässä valottaa taustalla 
olevia geenejä, jotka toimivat välittäjinä asbestin aiheuttamassa keuh-
kokarsinogeneesissä. Useita asbestiin liittyviä molekyylitason muutoksia 
voitaisiin käyttää asbestiin liittyvän ja liittymättömän keuhkosyövän 
erottavien diagnostisten menetelmien kehittämisessä.
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Asbestos has been used since ancient times by virtue of  its fl exible yet 
durable and fi re resistant properties. However, it was not until the second 
half  of  the 19th century, that the industrial applications of  asbestos be-
gan to be appreciated and its use increased markedly. The health effects 
of  asbestos exposure had already been noted by Roman naturalists, but 
the fi rst scientifi c indication that the fi bres were associated with several 
severe lung diseases came at the end of  the 19th century (reviewed in 
Liddell, 1997; Greenberg, 2004). The epidemiologic breakthroughs 
detailing the dangers associated with asbestos became publicized in the 
1950s and 60s (reviewed in Greenberg, 1982; Newman Taylor, 2009). 
Nonetheless, the material continued to play an important role in the 
construction industry until only a few decades ago and the asbestos 
industry was well over 100 years old before the cancer issues were fully 
recognized and addressed. 
Today the use of  asbestos has been banned in most developed coun-
tries due to the unequivocal evidence of  devastating asbestos-related 
diseases. However, in developing countries, asbestos is still utilized and 
WHO has estimated that approximately 125 million workers in the world 
are still being exposed to asbestos in their daily work environment (WHO, 
2007). Moreover, asbestos may not only affect workers, but also their 
families, through the exposure of  fi bres brought home on shoes, clothes, 
skin and hair (Kilburn et al., 1985). Therefore, the number of  exposed 
may be signifi cantly greater. Due to the long latency period of  30–40 
years, asbestos-related diseases will continue to burden public health 
also in developed countries (LaDou, 2004). Today, 20–40% of  adult 
men in the world are thought to have held jobs that could have entailed 
16
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asbestos exposure to some extent (Lin et al., 2007). Joiners, plumbers, 
electricians, painters, shipyard workers, builders, engineers, and asbestos 
miners are at the greatest risk (Currie et al., 2009).
Asbestos causes a variety of  malignant pleural diseases, such as 
asbestosis, mesothelioma and lung cancer. Mesothelioma is commonly 
recognized as the primary asbestos-related cancer type. Nevertheless, 
it has been estimated that asbestos gives rise to an equal number or 
possibly even more lung cancer cases as compared to mesothelioma. 
Various excess lung cancer to mesothelioma ratios have been reported, 
but a widely cited estimate is to expect between one and two excess lung 
cancers for every case of  mesothelioma (reviewed in Henderson et al., 
2004). Of  all lung cancers in the world, an estimated 5–7% are attribut-
able to occupational asbestos exposure (LaDou, 2004; Kamp, 2009).
Cancer arises from somatic cells which have been affected by succes-
sive molecular alterations occurring in a progressive, almost evolutionary, 
manner. These alterations evoke changes in normal cell functions, giving 
the cells the ability to transform into malignant derivatives. The six es-
sential changes in cell physiology that have been proposed to dictate the 
malignant growth of  perhaps all tumours are self-suffi ciency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of  apoptosis, 
limitless replicative potential, sustained angiogenesis and tissue invasion 
and metastasis. This multistep process normally takes several years to 
develop (Hanahan and Weinberg, 2000). The molecular alterations can 
be either genetic (physical alterations of  the DNA sequence, e.g. copy 
number alterations [CNA]) or epigenetic (e.g. promoter hypermethyla-
tion inhibiting gene transcription) leading to changes in the expression 
of  genes critical for the maintenance of  normal homeostasis. The 
genetic alterations may cause the duplication or even amplifi cation of  
so called oncogenes encoding for molecules (e.g. proteins) able to di-
rectly or indirectly enhance the ability of  the cells to become malignant. 
Deletion of  genetic material may cause the loss of  tumour suppressor 
genes encoding for molecules involved in the prevention of  malignant 
transformation (Ponder, 2001). During the past few decades it has be-
come more and more clear that it is not single oncogenes and tumour 
suppressors, but rather complex interactions between these genes and 
their products that are responsible for the changes in cell physiology 
17
INTRODUCTION
required for cell transformation. Several genes have also been found to 
act as both oncogenes and tumour suppressors depending on the con-
text or stage of  tumourigenesis (Bissell et al., 2005). Furthermore, some 
humans may have inherited a genetic alteration that is “advantageous” 
for the development of  cancer. However, the majority of  cancer-causing 
molecular alterations are environmental and life-style related (Peto, 2001; 
Boffetta, 2006).
Lung cancer is a complex type of  cancer and numerous genetic al-
terations are involved in its pathogenesis. The karyotype is chaotic, but 
recurrent alteration patterns have been identifi ed during several decades 
of  study (Balsara et al., 2002). It is well known that tobacco smoking is 
the primary predictor of  lung cancer. However, smoking in combina-
tion with asbestos exposure greatly elevates the risk of  lung cancer in 
an almost multiplicative manner (Vainio et al., 1994). Asbestos exposure 
alone also increases the risk of  lung cancer, but asbestos workers have 
been reported to have the highest percentage of  smokers compared to 
any other identifi able population; between 64–78% depending on the 
type of  occupation (Lange et al., 2006). This has proved to be one of  
the greatest challenges in studying asbestos-related lung cancer, i.e. the 
fact that two environmental exposures are often involved in the process 
of  malignancy development. The actual cause of  each individual lung 
cancer has been exceedingly diffi cult to elucidate. In addition, the long 
latency period from exposure to development of  lung cancer makes it 
diffi cult to draw conclusions about the molecular mechanisms generating 
the disease. Many of  the molecular alterations may be secondary or so 
called passenger alterations, induced by the primary possibly exposure-
specifi c alterations, which affect the stability of  the genome (Herceq et 
al., 2007). Currently, there are no clinically useful molecular alterations 
that can differentiate between asbestos-related and non-related lung 
cancer (Kamp, 2009).
Asbestos-related lung cancer has a very dismal prognosis, as do all 
lung cancers, even though the risk groups are well known. The current 
clinical methods for screening for lung cancer in risk groups have not 
improved mortality during the last few decades (Silvestri et al., 2009). The 
discovery of  distinct molecular alterations related to asbestos exposure 
may broaden the potential of  molecular diagnostics in these cancers. 
18
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Today the etiology is defi ned based on occupational history and pul-
monary fi bre count. Potential specifi c asbestos-related alterations could 
also assist in the detection of  early stage cancer in risk groups. Finally, 
understanding the molecular basis may eventually lead to the develop-
ment of  specifi c therapeutic approaches.
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1. Lung cancer
1.1 Epidemiology
During the 20th century lung cancer developed from a rare disease into 
a true epidemic and it is currently the most common type of  cancer in 
terms of  both incidence and mortality, being responsible for over 1.2 
million deaths every year in the world. In Europe and North America, 
lung cancer is the primary cause of  cancer related death and it is becom-
ing increasingly more common also in Asia, Latin America and Africa 
(Figure 1). Overall, the rate of  lung cancer among men is decreasing, 
while it is increasing among women (Figure 2; reviewed in Brennan et 
al., 2000; Toh, 2009).
Smoking has been well known to be the primary risk factor for lung 
cancer since the 1920’s (Tylecote, 1927). The risk depends largely on the 
amount and duration of  smoking, with a clear dose-dependent response 
having been shown in virtually all studies. Roughly, it can be estimated 
that approximately 1 in 10 lifetime smokers will develop lung cancer 
(reviewed in Hansen, 2008).
Occupational exposures mainly target the lung through inhalation 
and indeed, these kinds of  exposures play an important role in the risk 
of  developing lung cancer. Metals such as arsenic, ionizing radiation such 
as radon gas and respirable fi bers such as asbestos are some well docu-
mented exposure types that are able to induce lung cancer (Siemiatycki 
et al., 2004). An estimated 10–15% of  all lung cancers are caused by fac-
tors other than active smoking (Samet et al., 2009). Asbestos exposure 
is the leading cause of  occupational cancer in most countries and it is 
believed to be the second most important cause of  lung cancer after 
tobacco smoking (Anttila et al., 1993; Hagemeyer et al., 2006).
20
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Figure 1. Geographical distribution of lung cancer. Distribution of lung 
cancer incidence in A) males and B) females. Figure produced in GLOBOCAN 
2002 (Ferlay et al., 2004)
A)
B)
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The prognosis for lung cancer is generally very poor, depending 
largely on the histology and stage at diagnosis. In approximately three-
quarters of  the cases, distant metastatic spread is evident at the time of  
diagnosis, resulting in a fi ve-year survival of  about only 15% (reviewed in 
Hansen, 2008). During the past decades none of  the screening programs 
tested have shown any clear benefi ts (reviewed in Field et al., 2008).
1.2 Histology
Lung cancer can be divided into two major histological types, non-small 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This dis-
tinction is clinically important because of  the differences in presenta-
tion, metastatic spread and response to therapy. NSCLC can further be 
divided into the major subtypes adenocarcinoma (AC), squamous cell 
carcinoma (SCC) and large cell lung cancer (LCLC). Minor subtypes 
Figure 2. Lung cancer incidence. Lung cancer incidence in Finnish males 
and females between 1955 and 2005. Figure obtained from the Finnish 
Cancer Registry (www.cancerregistry.fi).
22
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include adenosquamous carcinoma (AC/SCC) and large cell neuroen-
docrine carcinoma (LCNEC) (Hansen, 2008; Travis et al., 2004).
AC accounts for around 40% of  all lung cancers. AC is the predomi-
nant subtype among young, female and non-smoking patients (Lee et al., 
1998; Subramanian et al., 2007). It has also been postulated that AC is 
the most common subtype among asbestos-exposed patients. However, 
this fi nding remains controversial and not all studies have reported such 
an association (reviewed in Henderson et al., 2004). AC usually originates 
in the peripheral lung tissue (Hansen, 2008).
SCC accounts for about 30–35% of  all lung cancers. It is strongly as-
sociated with smoking, with over 90% occurring in smokers. The primary 
location of  SCC is central and more often in the segmental bronchi than 
in the lobar and mainstem bronchi (Hansen, 2008). The frequency of  
this type of  tumour has been declining progressively, while that of  AC 
has been increasing possibly due to the introduction of  low-tar fi ltered 
cigarettes. The fi lters change the composition and anatomic distribution 
of  the carcinogenic particles (LaCroix et al., 2008). In addition, smokers 
of  low-tar fi ltered cigarettes seem to inhale smoke more deeply than 
smokers of  non-fi ltered cigarettes, which may cause the exposure of  
more peripheral areas of  the lungs (reviewed in Hoffmann et al., 1996).
LCLCs comprise between 5 and 10% of  all lung cancers and are 
poorly differentiated tumours which often arise in the lung periphery. 
There are several variants of  LCLC, for example LCNEC (Hansen, 
2008).
AC/SCC is a combination of  each histological type. It is rather 
rare, accounting for only approximately 0.6–2.3% of  all lung cancers 
(Hansen, 2008).
SCLC is responsible for around 25% of  all lung cancers and includes 
also combined SCLC, presenting cells of  any NSCLC subtype to dif-
ferent degrees. Together with SCC, SCLC is strongly associated with 
tobacco smoking and often occurs in central bronchial locations (Sun 
et al., 2007; Hansen, 2008).
1.3 Genetics and epigenetics 
The continuous exposure of  the lungs to carcinogens leads to the ac-
cumulation of  molecular alterations and lung cancer is characterized by 
23
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its large number of  genetic and epigenetic alterations, affecting almost all 
chromosomes (reviewed in Panani et al., 2006). Many of  the alterations 
are due to the widespread genetic instability affecting these tumours, 
but also recurrent alterations, apparently associated with the initiation 
and progression of  the tumours, can be observed.
The genetic alterations are mainly unbalanced with balanced translo-
cations being rare (Balsara et al., 2002). Frequent recurrent CNA in the 
lung cancer genome include loss of  3p, 4, 5q, 8p, 13q and 17p and gain 
of  1q, 3q, 5p and 8q (Figure 3; reviewed in Panani et al., 2006; Nymark, 
2009; Baudis, 2009). Different histological types exhibit slightly different 
patterns, for example gain of  3q has been associated with SCC (Tonon 
et al., 2005), while gain of  5p has been shown to be the most frequent 
change (60%) in AC (Weir et al., 2007).
CNAs often lead to allelic imbalance (AI), where one of  the two al-
leles of  a gene is lost, gained or amplifi ed. AI can also be copy number 
neutral, where one allele has been lost but the other duplicated, which is 
referred to as uniparental disomy (UPD) (reviewed in Tuna et al., 2009). 
Loss of  heterozygosity (LOH) describes the type of  AI where one of  
the two alleles has been lost. If  the other allele has already been inac-
tivated by some other means, for instance by mutation or methylation, 
this may lead to a total loss of  activity, e.g. of  a tumour suppressor. In 
cancer, whole, terminal and interstitial chromosome deletions, as well as 
unbalanced translocations have been shown to lead to LOH (Ogiwara 
et al., 2008). In lung cancer, AI can be detected in most of  the regions 
with CNA, though it is especially frequent at two regions; 3p14, which 
contains the tumour suppressor gene FHIT, and 3p21.3 (Zabarovsky 
et al., 2002).
Another type of  genetic alteration is point mutation, which in lung 
cancer is common, especially in the genes TP53, EGFR and KRAS. 
These point mutations have, in addition to LOH at 3p, 9p21 and 17p13, 
been demonstrated to be early events during multistage lung carcino-
genesis. Other CNA are thought to be relatively late events associated 
with tumour phenotype and metastatic behaviour (reviewed in Herbst et 
al., 2008; Soh et al., 2008). However, different types of  exposures have 
been linked to different types of  alterations and e.g. tobacco smoke is 
closely associated with point mutations and promoter hypermethylation 
(reviewed in Hecht, 1999), while asbestos exposure tends to be associ-
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ated with DNA loss and chromatid breaks (Huang et al., 1978; Hei et al., 
1992; Lohani et al., 2002; Msiska et al., 2009; Pelin et al., 1995; Valerio 
et al., 1980; Xu et al., 2007). Therefore, the early changes in tobacco-
related and asbestos-related lung cancer may be different. An example 
can be made of  the tumours in smokers and non-smokers, in which 
the genetic alterations appear to differ extensively. The chromosomal 
regions 9p21, 12p, 16p, 16q, 17q and 19q13 have been reported to be 
affected by alterations more frequently in AC of  never-smokers than in 
those of  smokers (Sanchez-Cespedes et al., 2001). Furthermore, TP53 
and KRAS mutations have been associated with lung cancer of  smok-
ers, while EGFR mutations are associated with those of  non-smokers. 
These differences have been shown to be important tools in the diag-
nosis, prognosis, clinical follow-up and targeted therapies in lung cancer 
patients (reviewed in Subramanian et al., 2008).
Inherited genetic alterations or polymorphisms, such as single 
nucleotide polymorphisms (SNP) and DNA copy number variations 
(CNV) may be advantageous for the development of  cancer. Indeed, 
lung cancer susceptibility has been shown to be increased in several in-
herited cancer-syndromes caused by germ-line mutations in TP53, RB1 
and EGFR. Lung cancer itself  is, however, rarely familial and few large 
families with multiple cases of  lung cancer are available for genome wide 
association studies of  SNPs and CNVs (reviewed in Herbst et al., 2008). 
Nevertheless, a few large studies have identifi ed an association between 
lung cancer susceptibility and SNPs at 6q23-25, 13q13.3 and 15q24-
15q25.1 (You et al., 2009; Li et al., 2010; Liu et al., 2008). The region at 
15q contains two genes encoding subunits of  the nicotine acetylcholine 
receptor alpha, which is regulated by nicotine exposure. Furthermore, 
deleting CNVs in the tobacco-carcinogen detoxifying gene GSTM1 has 
been shown to increase the risk of  lung cancer (Lam et al., 2009). Several 
other genes related to the metabolism of  tobacco-borne carcinogens, as 
well as genes associated with DNA repair and infl ammation, have been 
studied as hereditary risk factors, but the results require verifi cation in 
large study populations (reviewed in Foulkes, 2008).
The ploidy is often altered in lung cancer. Normal human lung cells 
show a diploid genome, but in lung cancer, the presence of  a near-triploid 
genome is common and around 50–60% of  all lung cancers can be said 
to be polyploid containing >57 chromosomes per nucleus (Testa et al., 
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1992; Hoglund et al., 2004). LCLC more often shows polyploidy than 
the other histological types (Desinan et al., 1996). Polyploidy has been 
associated with tumour infi ltration into the pleura (Desinan et al., 1996). 
Epigenetic alterations are defi ned as mitotically or meiotically herit-
able changes in gene expression that are not caused by alterations in the 
DNA sequence. DNA methylation and histone modifi cation are the two 
major epigenetic alterations involved in human carcinogenesis. DNA 
methylation is involved in normal cellular gene expression regulation 
and abnormal promoter hypermethylation may lead to the silencing of  
a gene (Jones et al., 2002). In lung cancer, promoter hypermethylation is 
common in tumour suppressor genes, such as P16/CDKN2A, RASS-
F1A and RB1 (reviewed in Pfeifer et al., 2009). Histone modifi cations 
control the accessibility of  the chromatin and may inhibit or activate 
transcription. These types of  modifi cations have also been implicated 
in the pathogenesis of  lung cancer (Bowman et al., 2006). 
CNA, point mutations, inherited genetic variations, polyploidy and 
epigenetic alterations may lead to changed expression of  the affected 
genes and subsequently to disruption of  whole signalling pathways. In 
addition to affecting the traditional protein coding genes, these altera-
tions may also evoke the dysregulation of  other types of  genes, e.g. 
those encoding for microRNAs (miRNAs). A new era in the fi eld of  
cancer investigation was recently opened with the discovery of  these 
non-coding RNAs, which regulate the expression of  an estimated 30% 
of  all human genes. During only a few years of  study miRNAs have 
been shown to be extremely useful in the characterization of  cancers 
(reviewed in Croce, 2009). Several miRNAs have been identifi ed as be-
ing dysregulated in lung cancer (Yanaihara et al., 2006). Consequently 
the main pathways affected in lung cancer are those involved in growth 
promotion (e.g EGFR), growth inhibition (e.g TP53 and p16INK4a-RB), 
apoptosis (e.g BCL-2) and DNA repair (reviewed in Sato et al., 2007; 
Brambilla et al., 2009). 
1.3.1 Methods used in the detection of genetic alterations and 
gene expression
CNAs can be detected by using comparative genomic hybridization 
(CGH), which was originally developed by Kallioniemi et al. (1992). In 
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this method, fragmented labelled tumour DNA competes with differ-
ently labelled, fragmented control DNA in a hybridization to a normal 
genome. The normal genome may be in the form of  a metaphase spread 
(chromosomal CGH or cCGH) or as several thousands of  spotted 
fragments on a microarray (array CGH or aCGH). The ratio between 
the signal intensities of  the different labels can then be measured auto-
matically and over- or under-representation of  genetic material in the 
tumour DNA is scored.
The different types of  AI can be detected by utilizing e.g. microsatel-
lites in the loci of  interest and performing fragment analysis on the PCR 
products from those loci (Slebos et al., 2004). Microsatellites are short 
sequence repeats in the genome, which may differ in length, i.e. number 
of  repeats, between the two alleles. Patients that are heterozygous for a 
microsatellite can be analyzed for the presence of  AI in that region, in 
the tumour DNA. The proportion of  one allele relative to the other can 
then be measured at a given microsatellite locus. The allele ratio in the 
tumour DNA is compared to the allele ratio in normal DNA from the 
same patient. Basically, microsatellite analysis to detect AI is another way 
of  identifying CNA in tumour samples, but also UPD can be detected 
with this method in contrast to CGH.
Polyploidy cannot be detected with CGH. Instead fl ow cytometry or 
karyotypic analyses for example using fl uorescence in situ hybridization 
(FISH), are needed (D’Urso et al., 2010). FISH, which was originally de-
veloped by Pinkel et al. (1986), uses fl uorescent probes, which hybridize 
to whole chromosomes or to specifi c chromosomal regions. The probes 
are applied to interphase, metaphase or tissue preparations and analyzed 
for the presence of  fl uorescent signals using a microscope. CNA can 
also be analyzed by FISH, usually using a centromeric probe together 
with a locus-specifi c probe in dual-colour hybridizations.
Gene expression changes in lung tumours compared to normal 
lung tissue can be studied using high-throughput methods such as gene 
expression microarrays, which estimate the mRNA expression level of  
tens of  thousands of  genes (Ramsay, 1998). There are several different 
types of  microarrays. Today, oligonucleotide arrays are a widely used type; 
they contain tens of  thousands of  short sequenced probes designed to 
match parts of  known or predicted genes.
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1.3.2 Gene Ontology (GO)
The Gene Ontology (GO) Consortium has attempted to produce a 
systematic description of  genes and their products, classifying them into 
so called ontologies. There are three major ontologies, namely biologi-
cal process, molecular function and cellular compartment. These three 
ontologies are structured vocabularies or networks of  terms, where each 
term is a so-called “child” of  one or more than one “parent” term. The 
child terms are more specialized, while the parent terms are more general 
(The Gene Ontology Consortium, 2001).
The GO terms can be used to facilitate the interpretation of  data from 
high-throughput analysis methods such as gene expression microarrays. 
By using the GO annotations, it is possible to analyze genes at group 
level, i.e. with a common nominator such as biological process. This type 
of  analysis is benefi cial in array experiments where the expressions of  
several thousands of  genes are monitored at the same time. Moderate 
changes in a group of  genes operating in the same biological process 
could refl ect signifi cant differential expression of  the whole pathway.
In lung cancer, some of  the dysregulated biological processes have 
been reported to be cytokine-cytokine receptor interactions, focal adhe-
sion, the MAPK signalling pathway, DNA replication and repair, protein 
targeting and transport as well as sodium ion transport (Chang et al., 
2007; Dehan et al., 2007; Gusev, 2008).
2. Asbestos
2.1 Characteristics
Asbestos is a common term for industrially refi ned and produced fi brous 
silicate minerals. Asbestos can be classifi ed into six distinct mineralogical 
types based on the chemical composition and physical appearance of  
the fi bres, i.e. chrysotile, crocidolite, amosite, tremolite, anthophyllite, 
and actinolite. Chrysotile belongs to the serpentine group and is a curly, 
thin fi bre. The other fi ve belong to the amphibole group of  minerals, 
which are longer and needle-like (LaDou, 2004).
The fi bers are composed of  hydrated magnesium silicates containing 
various amounts of  iron. Amosite and crocidolite contain the largest 
amounts of  iron (~27%) within the crystal structure, while chrysotile 
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Figure 4. End-use for asbestos in the United States in 1965. Figure pro-
duced with data from Virta, 2005.
contains less iron (2–6%) on the surface of  its crystal structure. Iron 
is believed to be important in the biological effects of  asbestos, since 
it can catalyze reactions which generate reactive oxygen and nitrogen 
species (ROS and RNS), which in turn induce oxidative stress in the 
cells (Peterson et al., 1998).
2.2 Use
The use of  asbestos peaked in Western Europe, North America, Japan 
and Australia in the 1970’s when it was advertised as a miracle compound 
for its fl exible and fi re resistant properties, although the fi rst suspicions 
about its harmful effects had been reported as early as 1898 (reviewed in 
Tweedale, 2001; Virta, 2006). Asbestos fi bres can be found in a multitude 
of  products such as heat, fi re and acid resistant coatings, gaskets, pipes, 
cement, insulation, fl ooring, roofi ng and several other types of  build-
ing material (Figure 4), as well as in lawn furniture, asphalt, car brakes 
and stage curtains (Figure 5; reviewed in Virta, 2005). A cigarette with 
a supposedly health protective fi lter containing crocidolite asbestos was 
even launched in 1952 and sold at least until 1956 (Figure 6) (Longo et 
al., 1995).
Asbestos cement - 
187 000t - 26%
Flooring products - 
181 000t, 25%
Roofi ng products - 
72 000t, 10%
Friction products - 
64 000t, 9%
Electrical products - 
22 000t, 3%
Packing and gaskets 
- 22 000t, 3%
Textiles - 15 000t, 2%
Other - 159 000t, 22%
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Figure 5. A 1950’s advertisement for asbestos in Harper´s magazine. 
Figure reproduced with permission from the UK Asbestos Services (www.
asbestosservices.com).
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Today the majority of  the asbestos produced is used in Eastern Eu-
rope, Latin America and Asia (Consensus Report, 1997; LaDou, 2004; 
Lin et al., 2007). In most of  the Western world and in Japan, the use 
of  asbestos in manufacturing or building has been banned or at least 
subject to strict control for the last 20–30 years, and asbestos demoli-
tion work is tightly regulated by law. In Finland, the use of  asbestos has 
been forbidden in building materials since 1988, but a complete ban 
on asbestos was introduced as late as 1994 (Finnish government deci-
sion 1380/1994). The leading asbestos producing countries are Russia, 
China, Kazakhstan, Canada and Brazil (Hetherington, 2008). Chrysotile 
is the most commonly used and economically important asbestos type 
(LaDou, 2004).
Figure 6. A 1960 advertisement for Kent cigarettes in the New York 
Mirror magazine. Micronite filters contained crocidolite asbestos for a few 
years during the 1950’s. Figure reproduced under “fair use” from Levin, 1987.
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2.3 Toxicity and carcinogenicity
The genotoxic and carcinogenic effects of  asbestos depend largely on 
the fi bre’s chemical composition and structure as well as the cell envi-
ronment (Mossman et al., 1998). A number of  in vitro and in vivo studies 
have shown that the longer the fi bre, the more carcinogenic it is per 
se (Donaldson et al., 1989). However, other researchers have claimed 
that fi bres of  all lengths induce pathological responses and no type of  
asbestos should be considered as being non-carcinogenic, simply based 
on its fi bre length (Dodson et al., 2003). Furthermore, on an epidemio-
logical basis, it has been diffi cult if  not impossible to establish such a 
hypothesis, since asbestos workers are often exposed to a mixture of  
different fi bre types and sizes (Anttila et al., 1993).
Due to the metals, the fi bre structure and their bio-persistence, the 
amphiboles are thought to be more pathogenic in the human body com-
pared to chrysotile. In contrast to chrysotile asbestos, which becomes 
fragmented and cleared from the lungs, amphiboles are considered to 
be totally insoluble in human lung (Stanton et al., 1972; Bernstein et al., 
2006). However, there is considerable controversy regarding the malig-
nancy risks associated with chrysotile exposure. It has been estimated 
that several hundred times the levels of  amphibole fi bres are needed to 
induce a similar risk of  malignancy with chrysotile (reviewed in Kamp, 
2009). Nevertheless, there is considerable pathological as well as experi-
mental evidence that also chrysotile is highly carcinogenic (Nicholson, 
2001; Pezerat, 2009; Suzuki et al., 2005). In fact, it has been established 
that chrysotile is as potent as crocidolite in its ability to cause lung can-
cer, even though it is 2–4 times less potent in evoking mesothelioma 
(Landrigan et al., 1999).
Asbestos fi bres enter into the lungs by inhalation. Once inside the 
lungs, the fi bres are surrounded by alveolar macrophages (AM). The AM 
deposit a protein coating around the fi bres, which are then referred to 
as asbestos bodies (see cover picture of  this thesis). However, due to 
the larger size of  the fi bres compared to the AM, so called frustrated 
phagocytosis may take place, leading to elevated release of  ROS and 
RNS (Mossman et al., 1998). Amphibole fi bres contain high levels of  
associated mono- di- and trivalent metals such as iron and it has also 
been proposed that asbestos is toxic by the particular way iron is bound 
to the fi bre’s surface, enabling generation of  ROS and RNS (Lund et al., 
1992; Gazzano et al., 2007).
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In addition to the generation of  ROS/RNS, the main mechanisms 
behind the toxic effects of  asbestos are thought to be alterations in 
mitochondrial function, mechanical disturbance of  cell cycle progres-
sion, and activation of  several signal transduction pathways (reviewed 
in Jaurand, 1997; Mossman et al., 1998; Upadhyay et al., 2003; Figure 
7). Many of  these effects are due to the triggering of  universal cellular 
responses, induced by several types of  cytotoxic substances. However, in 
vitro studies have also shown that asbestos fi bres are clastogenic (able to 
induce disruptions and breaks in chromosomes), even though they are 
not mutagenic in the Ames assay (Daniel, 1983; Hei et al., 1992). These 
genetic alterations are thought to contribute to the carcinogenic effects 
of  asbestos. Experimental studies as well as studies on lymphocytes from 
asbestos workers, have demonstrated asbestos-induced clastogenicity, in-
volving DNA single and double strand breaks, deletions, increased sister 
chromatid exchanges (SCE) and formation of  micronuclei (Dopp et al., 
1997; Dopp et al., 2005; Fatma et al., 1991; Fatma et al., 1992; Hardy et 
al., 1995; Lu et al., 1994; Marczynski et al., 1994; Hei et al., 1995; Msiska 
et al., 2009; Hei et al., 1992; Huang et al., 1978; Lohani et al., 2002; Xu 
et al., 2007). DNA double-strand breaks are the most severe types of  
DNA damage that can lead to translocations and chromosomal instabil-
ity (CIN), since they are more diffi cult to repair than for example DNA 
single-strand breaks. Crocidolite asbestos has been shown to be able to 
induce greater amounts of  DNA double-strand breaks than silica and 
titanium dioxide (Msiska et al., 2009). In addition, asbestos has been 
reported to cause abnormal chromosome segregation, which can not 
only lead to chromosomal deletions and other DNA alterations but also 
to aneuploidy (Fatma et al., 1991). The fi bres have also been shown to 
sterically block cytokinesis, leading to binucleated cells and consequently 
polyploidy (Jensen et al., 1996).
Several studies have shown that asbestos is able to induce transforma-
tion of  both murine and human cells (reviewed in Barrett et al., 1989). 
Nevertheless, the exact molecular mechanism behind asbestos-related 
carcinogenesis is still unresolved. It is thought to be very complex, prob-
ably involving several parallel pathways (reviewed in Nymark et al., 2008).
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2.4 Asbestos and tobacco smoke as co-carcinogens
Asbestos elevates the risk of  contracting lung cancer in non-smokers, but 
the risk seems to increase even more signifi cantly in smokers, indicating 
that tobacco smoke and asbestos act as co-carcinogens in a synergistic 
manner (Nelson et al., 2002). Various joint effects ranging from less than 
additive to more than multiplicative have been reported, but the gener-
ally accepted model that seems to fi t the best is a more than additive or 
less than multiplicative one (Henderson et al., 2004).
Several mechanisms are likely to contribute to the synergistic effects 
of  these two carcinogens. For example, there are studies demonstrating 
that cigarette smoke augments the penetration of  asbestos fi bres in rat 
tracheal explants by an oxygen radical-mediated mechanism (Churg et al., 
1989). Tobacco smoke may also interfere with the clearance of  asbestos 
fi bres from the lungs (Henderson et al., 2004). Conversely, tobacco car-
cinogens are known to be adsorbed onto the surface of  asbestos fi bres 
increasing their uptake into the cells (Fournier et al., 1986; Nelson et al., 
2002). In addition, ROS have been observed to alter the metabolism of  
the tobacco carcinogen, benzo[a]pyrene, by inhibiting its detoxifi cation 
pathways (Flowers et al., 1991). Yet another hypothesis is that asbestos 
fi bres induce cell proliferation and thereby clonal expansion of  cells 
with heritable tobacco carcinogen-induced alterations in critical genes 
(Haugen et al., 1982).
3. Asbestos-related lung cancer
In numerical terms, asbestos-related lung cancer is considered to be 
the most important occupational cancer in the world (Karjalainen et al., 
1994). In Finland, there are around 2000 lung cancer cases every year 
and approximately 90 of  these are reported to be of  occupational origin 
and associated with asbestos.
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Table 1. Relative risks of lung cancer associated with different levels 
of tobacco smoke and asbestos exposure. Modified from Gustavsson 
et al. (2002).
Asbestos 
exposure 
(fiber-
years1)
Smoking (cigarettes per day)
0 1–10 11–20 >20
RR2 (95% CI3)
0 1 10.5 (6.7–16.6) 23.3 (15.2–35.8) 45.4 (28.6–71.9)
>0–0,99 1.8 (0.6–5.5) 18.1 (8.2–40.4) 17.0 (8.8–32.7) 38.5 (17.7–83.4)
1–2,49 2.7 (0.7–9.5) 12.1 (5.1–29.3) 29.8 (15.1–58.6) 36.8 (11.9–113.7)
≥2,5 10.2 (2.5–41.2) 13.56 (4.6–40) 86.2 (28.8–258.2) 80.6 (20.2–322.0)
1fibers/ml x years,2relative risk,3confidence interval
3.1 Lung cancer risk associated with asbestos 
exposure
The fi rst associations between asbestos exposure and lung cancer were 
made in 1935 (Gloyne, 1935; Lynch et al., 1935). Today, there is a large 
body of  epidemiological evidence demonstrating that asbestos exposure 
increases the risk of  lung cancer and, together with tobacco smoke, the 
risk is signifi cantly enhanced as described above in Section 2.4 (reviewed 
in Kamp, 2009). Not unexpectedly, the risk is highly dependent on the 
duration and amount of  exposure as demonstrated in Table 1 (Gustavs-
son et al., 2002). Depending on the study, the relative risk (RR) of  lung 
cancer due to asbestos exposure has been estimated to be between 0.83 
and 25, due to smoking between 1.78 and 10.85 and for both exposures 
combined, between 4.51 and 53.24 (reviewed in Lee, 2001; Reid et al., 
2006; Wraith et al., 2007). Inaccuracies in both self-reported occupa-
tional exposure and in differences in the exposure level depending on 
the type of  work have made it very diffi cult to determine the actual 
RR associated with asbestos exposure and smoking on their own or 
in combination. This may explain the broad range of  RR in different 
studies (Bakke et al., 2001).
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Asbestos-related lung cancer is largely gender dependent, but this is 
due to the low numbers of  female workers in the construction, shipyard 
and asbestos industries. The ratio of  men to women among asbestos-
related lung cancer patients is approximately 32:1, compared to about 
4.5:1 for all lung cancers (Karjalainen et al., 1994).
3.2 Clinical features
Asbestos exposure has been associated with lower-lobe and a peripheral 
location of  the tumour as well as with AC histology in some studies 
(Anttila et al., 1993; Karjalainen et al., 1994; Paris et al., 2003). In con-
trast, tobacco smoking has been associated with upper-lobe and cen-
tral location as well as SCC and SCLC. However, the asbestos-related 
observations remain controversial, since not all studies have detected 
such associations (Lee et al., 1998; reviewed in Henderson et al., 2004). 
The contrasting results may be due to different types of  exposures in 
different populations. For example, Finnish asbestos workers have often 
been exposed to larger amounts of  antophyllite and crocidolite than 
those reported in Britain and North America, which have been primarily 
exposed to chrysotile (Anttila et al., 1993).
Asbestosis is a type of  pleural fi brosis, i.e. chronic infl ammation 
and scarring of  the lung tissue caused by the inhaled fi bres (Huggins 
et al., 2004). While it has been proposed that asbestosis must precede 
the development of  asbestos-related lung cancer, there is considerable 
evidence that lung cancer can develop also without the presence of  
asbestosis. Indeed, asbestos has been shown to be able to act as an inde-
pendent carcinogen on all the critical steps of  malignant transformation 
of  a cell, i.e. initiation, promotion and progression (reviewed in Kamp, 
2009). Nevertheless, it is generally agreed that the presence of  asbestosis 
greatly increases the risk of  lung cancer in a manner that is similar to 
the presence of  other types of  pulmonary fi brosis. Whether asbestosis 
is simply a marker of  high-dose asbestos exposure or if  it is necessary 
for attributing an individual’s lung cancer to asbestos exposure, remains 
a matter of  debate (reviewed in Hessel et al., 2005).
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3.3 Molecular alterations attributable to asbestos 
exposure in lung cancer
The fact that most asbestos-exposed lung cancer patients are also tobacco 
smokers has made it very diffi cult to differetiate the asbestos-related 
molecular changes from those attributable to tobacco carcinogens by 
molecular epidemiology (Nelson et al., 2002). However, several attempts 
have been made and some molecular alterations associated with asbestos 
have been identifi ed. Many of  the studies are experimental, but a few 
have also been performed on primary lung cancer samples. Some of  
the most noteworthy alterations, which have been reported more than 
once, are listed in Table 2.
3.3.1 Genetic alterations
A few CNA have been associated with asbestos exposure in lung cancer. 
For example, Dopp and co-workers have demonstrated on experimental 
level that the centromeric regions of  chromosomes 1 and 9 are affected 
by DNA breakage following asbestos exposure in human amniotic fl uid 
cells and lymphocytes (Dopp et al., 1997; Lohani et al., 2002). Another 
study has shown that loss of  one or both copies of  chromosome 5, 
monosomy of  chromosome 19 and trisomy of  chromosome 8 are 
common changes in fi ve asbestos-transformed tumorigenic bronchial 
epithelial cell lines compared to the parental non-tumorigenic cell line. 
In addition, the asbestos-transformed cell lines display hypoaneuploidy 
with 42–44 chromosomes compared to the parental cell line with hy-
peraneuploidy containing 46–50 chromosomes (Suzuki et al., 2001). In 
contrast, as mentioned before asbestos has also been shown to cause 
polyploidy in vitro (Jensen et al., 1996). Both aneuploidy and polyploidy 
may lead to malignant cell transformation (Storchova et al., 2008).
All of  the chromosomes mentioned above have also been reported 
to be affected by alterations to different degrees in lung cancer in general 
(Figure 3; Baudis et al. 2001; Baudis, 2009). However, based on these 
results, in asbestos-related lung cancer they may potentially be primary 
alterations appearing at an early stage of  carcinogenesis. In fact, none of  
these chromosomes or regions appears to be affected by early changes in 
lung cancer in general (reviewed in Herbst et al., 2008; Soh et al., 2008). 
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As noted previously, asbestos has primarily been associated with 
deletions, breaks and fragments in the genome, while smoking is likely 
to cause point mutations and aberrant methylation of  genes. The P16/
CDKN2A gene has been found to be affected by both epigenetic 
(hypermethylation) and genetic (homozygous deletion and rare point 
mutations) alterations in lung cancer. In a recent study on primary 
lung cancer samples, homozygous deletions were found to correlate 
signifi cantly with asbestos exposure, while methylation of  the gene was 
confi rmed to correlate with smoking (Andujar et al., 2010). Interestingly, 
P16/CDKN2A is generally affected by homozygous deletions also in 
mesothelioma (reviewed in (Andujar et al., 2010)). 
Another chromosomal region, that seems to be affected more fre-
quently in asbestos-related than in non-related lung cancer, is 3p. LOH 
at 3p21.3 (Marsit et al., 2004) and 3p14 (FHIT) have been linked with 
asbestos exposure in primary lung cancer (Nelson et al., 1998; Pylkkänen 
et al., 2002b). However, this may be the effect of  the asbestos-induced 
clonal expansion of  cells with a tobacco smoke-related alteration, since 
these regions are often also affected in lung cancer without asbestos as-
sociation. Reduced expression of  FHIT has been shown to be equally 
frequent in both exposed and non-exposed lung cancer patients, indi-
cating that the gene is silenced by some additional mechanism in lung 
cancer of  non-exposed patients (Pylkkänen et al., 2002b). Indeed, this 
gene is frequently hypermethylated in smokers with early stage SCC 
(Kim et al., 2004).
TP53 has been one of  the most extensively studied genes in asbestos-
related lung cancer, as it is in cancer in general. This gene has been shown 
to be up-regulated by asbestos exposure and abnormal accumulation 
of  p53 is more frequent in tumours and serum of  asbestos-exposed 
patients compared to non-exposed subjects (Nuorva et al., 1994). Some 
studies have associated TP53 mutations with asbestos exposure in lung 
cancer (Liu et al., 1998; Lin et al., 2000; Panduri et al., 2006; Wang et al., 
1995), but the association remains controversial since others have not 
been able to confi rm these results (Husgafvel-Pursiainen et al., 1999). 
Similarly, there are controversial results regarding the KRAS gene, in 
which mutations have primarily been associated with smoking in lung 
cancer. A few studies have also reported correlations between its muta-
tion and asbestos exposure (Husgafvel-Pursiainen et al., 1993; Nelson 
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et al., 1999; Vainio et al., 1993), but not all (Hei et al., 1997; Husgafvel-
Pursiainen et al., 1999).
Individual susceptibility to asbestos-related lung cancer has been 
studied to some extent. However, few studies have been able to effi ciently 
evaluate the actual association of  the genetic variation, i.e. whether it 
modifi es the effect of  the asbestos exposure or that of  tobacco-smoke 
exposure (reviewed in Neri et al., 2008). The most convincing evidence 
has come from a study on the MPO gene, in which a polymorphism 
referred to as the A-allele genotype conferred a protective effect against 
cancer development in asbestos-exposed individuals, i.e. reducing lung 
cancer susceptibility (Schabath et al., 2002).
3.3.2 Signalling pathways
Cells depend on internal and external signals in order to maintain nor-
mal function and the balance of  this microenvironment is crucial for 
normal homeostasis. Changes in the signalling pathways of  the internal 
microenvironment may provide also surrounding cells with growth 
promoting signals. Expressional changes in central genes caused by 
molecular alterations in the DNA may alter these signalling pathways 
(Hanahan and Weinberg, 2000). Carcinogenic substances may also alter 
gene expression by binding to receptors or transcription factors prior 
to any genetic alterations. Indeed, asbestos has been shown to bind to 
several specifi c proteins involved in the cell cycle as well as in cytoskeletal 
and mitotic processes (MacCorkle et al., 2006).
The main signalling pathways that have been found to be affected 
by asbestos exposure include those involved in oxidative stress, infl am-
mation, DNA repair, mitochondrial activity and apoptosis (Figure 7 and 
Table 2; Upadhyay et al., 2003; Jaurand, 1997). As mentioned before, 
many of  these changes are probably the consequences of  normal cellular 
responses to foreign toxic particles. However, they may nevertheless be 
involved in the carcinogenic effects of  asbestos in combination with the 
more specifi c clastogenic properties of  the fi bres.
Asbestos induced oxidative stress and infl ammation directed path-
ways are intertwined and complex involving the induced expression of  
several genes such as TNFα and NF-κB subunits as well as EGFR and 
MAPK (Figure 7, reviewed in Shukla et al., 2003b). In addition, antioxi-
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dant enzymes and peptides, such as superoxide dismutase (SOD) and 
glutathione have been proposed to be involved in the pathogenesis 
of  asbestos-related lung cancer, causing disturbances in the oxidant-
antioxidant balances and subsequently reducing the cell’s capability to 
protect itself  against ROS and RNS (Bhattacharya et al., 2005; Fattman 
et al., 2006; Pande et al., 2006; Puhakka et al., 2002; Tan et al., 2004; 
Wang et al., 2006).
DNA damage repair pathways are up-regulated in asbestos-treated 
cells (Upadhyay et al., 2003). In particular, the genes TP53 and CDKN1A 
(encoding for Cip1, also known as p21) have been found to be expressed 
at higher levels following asbestos exposure (Johnson et al., 1997; Piao 
et al., 2001; reviewed in Kamp, 2009). Over-expression of  TP53 should 
assist the DNA repair processes, however if  the gene is mutated it may 
render the protein non-functional or malfunctional (Schetter et al., 2009).
Apoptosis protects against abnormal proliferation of  cells with 
non-repairable DNA damage. However, if  the apoptotic pathways are 
bypassed, then the asbestos-associated dysfunctions in the mitochon-
drial respiratory chain maintain an increased release of  ROS, creating a 
continuous supply of  these damaging molecules (Shukla et al., 2003a). 
Several apoptosis-related genes have been identifi ed in asbestos-induced 
apoptotic resistance, especially BCL2 and BCL2-related genes seem to 
have a central role (Kamp et al., 2002; Miura et al., 2006; Narasimhan 
et al., 1998).
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AIMS OF THE STUDY
Lung cancer is strongly associated with inhaled exposures such as to-
bacco smoke and asbestos fi bres. These exposures cause extensive DNA 
damage on their own as well as acting together as co-carcinogens. The 
resulting complexity of  the lung cancer genome has made it diffi cult 
to unravel specifi c molecular alterations associated with the different 
exposures. Tobacco-related molecular alterations have been identifi ed, 
whereas there are no specifi c molecular biomarkers associated with 
asbestos-related lung cancer. These molecular correlations could be of  
importance not only for the diagnosis, prognosis and treatment of  the 
disease, but also in the medico-legal aspects of  this occupational disease.
Therefore, the specifi c aims of  this thesis were to:
• Perform a global search for specifi c gene copy number alterations 
(CNA) differing between asbestos-related and non-related lung 
cancer (I)
• Validate and characterize the identifi ed asbestos-related CNAs in 
a larger study population (II–III)
• Profi le expressional changes in genes, pathways and specifi c chro-
mosomal regions in asbestos-exposed cell lines (IV)
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1. Lung cancer patients and DNA samples 
(I, II and III)
All the patients used in the studies of  this thesis were of  Finnish Cau-
casian origin with histologically confi rmed lung cancer. The tumours 
were classifi ed according to the latest WHO classifi cation (1999/2004). 
Two different collections of  samples were used in the studies (I, II, III; 
Table 3). All samples were analyzed by electron microscopy with energy 
dispersive spectrometry to determine their pulmonary asbestos fi bre 
concentration.
The fi rst collection (subsequently referred to as collection 1) consisted 
of  82 fresh-frozen lung tumour and adjacent normal samples from a set 
of  tissue samples obtained during lung cancer surgery at the Helsinki 
University Central Hospital in the 1980´s and -90´s. All the patients were 
personally interviewed about their smoking habits and work history, and 
provided their informed consent to take part in the study and to use 
their tissue. Thirty-six patients were current and 41 were ex-smokers, 
three were non-smokers; for two patients smoking data was missing. 
Forty-nine patients had less than 0.5 million fi bres per gram of  dry lung 
tissue (later referred to as fi bres/g) and 44 of  them did not have any 
known history of  asbestos exposure, while 5 had a probable history of  
exposure. Thirty-three patients had more than 1 million fi bres/g and 25 
of  them had a probable or defi nite history of  asbestos exposure. The 
Ethical Review Board for Research in Occupational Health and Safety 
and the Coordinating Ethical Review Board, Helsinki and Uusimaa 
Hospital District (75/E2/2001) approved the study protocols.
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The second collection (later referred to as collection 2) consisted of  
135 patients’ formalin-fi xed paraffi n embedded (FFPE) tumour sam-
ples, which had been obtained through surgery, bronchoscopy, lymph 
node biopsy or autopsy. Fifty-three patients had less than 0.5 million 
fi bres/g and 82 patients had more than 1 million fi bres/g. The samples 
of  these patients had originally been sent to the Finnish Institute of  
Occupational Health (FIOH) from different regions of  Finland for 
analysis of  pulmonary asbestos fi bre count as a part of  the diagnostic 
procedure during 1985–2006. Permission to use the diagnostic samples 
for research purposes was given by The National Agency for Medicole-
gal Affairs (4476/33/300/05) and the collection of  patient information 
for research was approved by the Ministry for Social Affairs and Health 
(STM/2474/2005).
Twenty-eight samples from collection 1 were included in study I 
(Table 3). Fourteen of  the samples originated from patients with a 
pulmonary fi bre count of  5 million fi bres/g or more and a defi nite or 
probable history of  asbestos exposure. The other fourteen samples 
originated from patients with 0.5 million fi bres/g or less and no known 
history of  asbestos exposure. Fourteen of  the samples were malignant 
lung tumours from highly asbestos-exposed patients and 14 tumours 
were from non-exposed patients that were matched for age, gender, 
nationality and smoking history. In addition, the distribution of  different 
tumour histologies was matched between the groups (Table 3).
In study II, 139 tumour samples from collections 1 and 2 were used. 
Seventy-seven samples originating from patients with a fi bre count of  
1 million or more fi bres were included in the exposed group. Sixty-two 
samples originating from patients with a fi bre count of  0.5 million 
fi bres/g or less made up the non-exposed group (Table 3).
In study III, 205 tumour samples from collections 1 and 2 were used. 
One-hundred and nine samples from patients with a fi bre count of  1 
million or more fi bres were included in the exposed group. Ninty-six 
samples from patients with a fi bre count of  0.5 million fi bres/g or less 
represented the non-exposed group (Table 3).
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A minimum of  1 million fi bres/g is usually considered a sign of  
occupational exposure to asbestos and increased risk of  lung cancer 
(Karjalainen et al., 1993; Karjalainen et al., 1994). Up to 1 million fi bres/g 
of  dry lung tissue have been reported to be detected in the general popu-
lation (Churg, 1997). Thus, it was decided to include cases with a fi bre 
count of  up to 0.5 million fi bres/g in the non-exposed group, but cases 
with more than 0.5 and less than 1 million fi bres/g were excluded from 
the study to highlight the contrast between exposed and non-exposed.
2. Cell lines (IV)
Three cell lines, A549, BEAS-2B and MeT5A, were used to study gene 
expression changes related to asbestos exposure. A549 is a human lung 
adenocarcinoma cell line, while BEAS-2B and MeT5A are human SV40-
transformed immortalized bronchial epithelial and pleural mesothelial 
cell lines, respectively. All three cell lines are well characterized and have 
been widely used in pulmonary research (Fung et al., 1997; Kahlos et al., 
2001; Pache et al., 1998; Perkins et al., 1999). The cells were cultured as 
described previously (Kinnula et al., 1996; Kinnula et al., 1998; Ollikainen 
et al., 2000; Puhakka et al., 2002). In brief, A549 cells (American Type 
Culture Collection, Rockville, MD) were cultured in nutrient mixture 
F-12 growth medium supplemented with 15% fetal calf  serum (FBS), 
100 U/ml penicillin and 100 mg/ml streptomycin at 37 °C in a 5% CO2 
atmosphere. The BEAS-2B cells (National Cancer Institute, Laboratory 
of  Human Carcinogenesis) were cultured according to the manufac-
turer’s instructions (bronchial epithelial cell growth medium (BEGM); 
Clonetics Inc., San Diego, CA). MeT5A cells (American Type Culture 
Collection) were cultured with RPMI 1640 medium containing 10% heat 
inactivated FBS, 0.003% L-glutamine, 100U/ml penicillin, and 100 mg/
ml streptomycin at 37 °C in a 5 % CO2 atmosphere.
2.1 Asbestos exposure
The cells were exposed to crocidolite asbestos in semi confl uent cell cul-
tures (2 μg/cm2 for A549 and BEAS-2B cells and 1 μg/cm2 for MeT5A 
cells; International Union Against Cancer, Johannesburg, South Africa). 
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The fi bre doses were chosen based on previous studies in our labora-
tory and by others (Kinnula et al., 1996; Ollikainen et al., 2000; Puhakka 
et al., 2002). Samples were collected from asbestos-exposed and non-
exposed parallel control A549 and BEAS-2B cells at 5 time points, i.e. 
0h (before any asbestos exposure or other treatment) and at 1h, 6h, 24h, 
and 48h. Additionally, a sample was collected from A549 cells at 7 days. 
Samples from the exposed and non-exposed control MeT5A cells were 
collected at 1h and 48h. The cultures and exposures were conducted on 
three or more separate tissue culture plates (T25 and T75), and the cells 
were pooled before RNA extraction to eliminate the need of  biological 
replicate hybridizations.
3. Analysis methods
3.1 Chromosomal and array CGH (I)
DNA was isolated from 28 tumour samples from exposed and non-
exposed patients and from peripheral blood from two male references 
using QIAamp DNA Mini Kit (QIAGEN®, Valencia, CA).
cCGH was performed on all 28 tumour samples. 1 μg of  digested and 
labelled reference (TexasRed-5-dCTP and -dUTP) and tumour (FITC-5-
dCTP and –dUTP) DNA was used for the hybridizations (NENTM; Life 
Science Products Inc., Boston, MA). The slides were hybridized over-
night at 37ºC and washed according to standard protocols (Björkqvist 
et al., 1998b). Isis CGH program (version 3; MetaSystems GmbH, 
Altlussheim, Germany) was used for the analysis. Twenty metaphases 
were analyzed for each sample. Standard cut-off  thresholds were set 
to <0.85 for deletions, >1.17 for gains and >1.5 for amplifi cations, as 
described by Björkqvist et al. (1998b).
aCGH analyses were conducted on twenty of  the same samples (11 
exposed and 9 non-exposed; see Table 1 in study I). cDNA microarrays 
(Human 1.0; Agilent Technologies, Palo Alto, CA) containing 12,814 
unique clones (97% map to named human genes) were used as described 
by Wikman et al. (2005). Briefl y, the hybridizations were performed 
with 5 μg of  digested (25U Alu1/25U Rsa1) reference and tumour 
DNA, labelled (Cy3 dUTP-tumour, Cy5 dUTP-reference; Amersham 
Pharmacia Biotech, Piscataway, NJ) using a random priming method 
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(RadPrime DNA Labelling System; Gibco BRL, Gaithersburg, MD). 
After hybridization at 65°C overnight, the slides were washed, dried 
in a centrifuge and scanned using Agilent’s DNA Microarray Scanner 
(G2565AA).
Feature Extraction software (Agilent Technologies) was used to 
measure raw signal intensities from the arrays. Measurements fl agged 
as unreliable were removed from subsequent analysis. Additionally, 
faulty measurements defi ned by our own image analysis methods were 
removed (Ruosaari et al., 2002). In order to identify exposure-related 
aberrations, the aCGH data from individual patients were analyzed at 
the group level by comparing gene copy number ratios of  the tumours 
from exposed and non-exposed patients. Exposure-related areas were 
identifi ed by using overlapping 0.5–1 Mbp segments that were tested 
for differences in copy numbers as described in the supplemental data 
of  the original publication (I).
3.2 Microsatellite analysis for detection of allelic 
imbalance (II and III)
Tumour cells were harvested with a Veritas Laser Capture Microdissec-
tion Instrument (Arcturus, Mountain View, CA, USA) from 8 μm tissue 
sections stained with 1% toluidine blue/0.2% methylene blue solution. 
DNA was isolated using a PicoPureTM DNA Extraction Kit (Arcturus) 
following the manufacturer’s instructions and stored at –20ºC.
In Study II, 15 microsatellite markers were analyzed at 9q31.3–q34.3 
with an average spacing of  1.8 Mbp (base pairs 112128955–139756701, 
27.7 Mbp, Figure 8a) in 52 fresh-frozen lung tumour and correspond-
ing normal samples from the same patients (collection 1, see section 1. 
of  Materials and Methods). The primer sequences for thirteen of  the 
microsatellite markers (D9S1675, D9S1683, D9S930, D9S289, D9S302, 
D9S1776, D9S170, D9S1872, D9S195, D9S1116, D9S1831, D9S1793 
and D9S1838) were obtained from the database of  the National Center 
for Biotechnology Information (NCBI). Two additional markers were 
identifi ed with Alex Dong Li´s RepeatFinder v4.0 (http://www.genet.
sickkids.on.ca/~ali/repeatfi nder.html) in the region 9q33.1 (TC-repeat 
and AC-repeat, base pairs 121021696-121168710, NCBI Build 36.1). 
Primers were designed with the Primer3 software (Rozen et al., 2000).
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D9S1872
D9S1776
D9S170
RP11-357D21
RP11-440N22
RP11-10I9
RP11-100C15
D9S930
D9S289
D9S302
TC repeat
D9S195
D9S1116
D9S1831
D9S1793
D9S1838
RP11-228B15
RP11-816F8
D9S1675
D9S1683
AC repeat
Microsatellite 
marker
BAC
9q32
9q33.1
9q33.2
9q33.3
9q34.1
9q34.2
9q34.3
9q11 (CEN)
9q
D2S378
D2S2153
D2S2251
D2S123
D2S2739
D2S391
D2S2182
D2S2378
D2S2240
D2S2174
D2S2298
D2S119
D2S2259
D2S2328
RP11-183P21
RP11-963J22
RP11-703K23
RP11-347F1
RP11-1114A19
2p16.1
2p22.1
2p16.2
2p16.3
2p21
2p11(CEN)
2p
Figure 8. Map of microsatellite markers, Bac probes and centromere 
probes on 9q (A) and 2p (B). The markers and probes are aligned to cor-
respond to each other’s physical position on the chromosomes.
A)
B)
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In Study III, 14 microsatellite markers (D2S2328, D2S2259, D2S119, 
D2S2298, D2S2174, D2S2240, D2S2378, D2S2182, D2S391, D2S288, 
D2S2739, D2S123, D2S2251, D2S2153, D2S378 from NCBI) were 
analyzed at 2p22–p16.1 with an average spacing of  1.2 Mbp (base pairs 
40532153- 57157077, 16.6 Mbp, Figure 8b) in 27 fresh-frozen lung 
tumour and corresponding normal samples from the same patients 
(collection 1).
All primers were synthesized and labelled with FAM™, HEX™ or 
NED™ fl uorochrome at TIB MOLBIOL Syntheselabor GmbH (Berlin, 
Germany). The target sequences were amplifi ed by PCR in a volume of  
10μl containing 200μM dNTPs, 700 mM of  each primer, 1x PCR Buffer 
containing 15 mM MgCl2, 0.25 units of  HotStarTaq DNA Polymerase 
(Qiagen) and genomic DNA from normal or tumour samples. An initial 
10 min, 95ºC denaturation step was followed by 40 cycles of  95ºC for 
40 s, 40 s at the optimized annealing temperature, and 72ºC for 1 min. 
The PCR products were analyzed with a 310 and a 3100-Avant Genetic 
Analyzer (Applied Biosystems, Foster city, CA) according to the manu-
facturer’s protocol.
GeneMapper Analysis Software versions 3.5 and 4 (Applied Bio-
systems) were used to study the lengths of  the allele fragments. The 
alleles were defi ned as the two highest peaks within the expected size 
range. According to standard procedures, the ratio of  the alleles’ peak 
heights between a patient’s tumour and normal samples was calculated 
for heterozygous markers. A ratio of  2.0 or higher was scored as AI.
The frequency of  AI was compared at the 9q and the 2p regions 
between the tumours of  the exposed and the non-exposed patients. Dif-
ferences within histological types were tested separately if  the number 
of  cases was suffi cient for testing. At 9q, tumours with more than 6 
informative microsatellite markers were assigned AI at the whole region 
if  more than 25% of  the markers showed AI. In addition, AI at 9q33.1 
was analyzed separately using 3 microsatellite markers (TC-repeat, AC-
repeat and D9S195) covering 0.15 Mbp. Tumours with an informative 
result from at least 2 markers were included in the analysis and AI at 
the region was scored for a tumour if  more than 1 marker displayed 
AI. In this thesis, the 2p region was analyzed in the same way as the 
9q region. Thus, tumours with more than 5 informative microsatellite 
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markers at 2p were assigned AI at the whole region if  more than 25% 
of  the markers showed AI. Also, 2p16 was analyzed separately includ-
ing 5 markers (D2S2739, D2S123, D2S2251, D2S2153 and D2S378) 
covering 7.7 Mbp. Tumours with an informative result from at least 2 
markers were included in the analysis and AI at the region was scored 
for a tumour if  more than 1 marker showed AI.
In the tumour DNA, the presence of  novel peaks of  a size that dif-
fered from those in the normal DNA by an integer number of  repeat 
units was defi ned as microsatellite instability (MSI).
Parallel replicates with two to three separate PCR reactions were 
performed for three markers on fi ve cases to ensure general reproduc-
ibility. If  replicates were performed, an average of  the ratios was used, 
although the results were highly congruent. 
3.3 Fluorescence in situ hybridization (FISH) 
(II and III)
3.3.1 Tissue microarrays
Five tissue microarray (TMA) blocks were designed with FFPE tumour 
material from 24–34 patients from collection 2. Two to four tissue 
cores with tumour material from each patient were included on the ar-
rays. Normal lymph node material, included in each TMA was used as 
normal controls.
3.3.2 Locus-specifi c FISH
The region 9q32-34.3 (base pairs 115085166-137867305; Figure 8a) was 
analyzed by fl uorescence in situ hybridization (FISH) using six bacterial 
artifi cial chromosome (BAC) probes (RP11–10I9, RP11–357D21, RP11–
440N22, RP11–228B15, RP11–816F8 and RP11–100C15; BAC PAC 
Resources, CHORI, Oakland, CA, USA) on 95 tumour samples from 
both collections (38 fresh-frozen and 57 FFPE; 48 asbestos-exposed 
and 47 non-exposed).
The region 2p21–p16 (base pairs 46081709–54680411; Figure 8b) was 
analyzed by FISH using fi ve BAC probes (RP11–1114A19, RP11–347F1, 
RP11–703K23, RP11–963J22, and RP11–183P21; BAC PAC Resources) 
53
MATERIALS AND METHODS
on 151 tumour samples from both collections (67 fresh-frozen and 84 
FFPE; 79 asbestos-exposed and 72 non-exposed).
Bacteria containing the BAC sequences were grown according to the 
manufacturer´s instructions (http://bacpac.chori.org/protocols.htm). 
DNA was extracted with a Qiagen Plasmid Purifi cation Kit (Qiagen, 
Valencia, CA, USA) and nick-translated (Nick Translation Kit, Vysis, Inc. 
/Abbott Molecular, Inc., Downers Grove, IL) followed by labelling with 
biotin-14-dATP (Invitrogen Life Technologies, Carlsbad, CA, USA) or 
fl uorescent Spectrum Green™ dUTP (Vysis, Inc. /Abbott Molecular, 
Inc., Downers Grove, IL, USA).
To ensure specifi c hybridization, the probes were hybridized to 
normal metaphases and histologically normal FFPE sample sections 
of  lung tissue or lymph nodes. Each probe was then hybridized on 
pretreated TMA slides and fresh frozen tumour sections. Pretreatment 
of  the slides was performed as follows: after paraffi n removal of  TMA 
slides and hydration of  slides with fresh-frozen samples, the sections 
were treated in 0.01M citrate, pH 6.0 at 80 ºC for 2 hours and digested 
with DigestAll™3 (Zymed Laboratories Invitrogen Immunodetection, 
San Francisco, CA) at 37 ºC for 10 min. Denaturation, dehydrations 
and hybridizations were performed as previously described (Kettunen 
et al., 2000). Biotin-labeled probes were visualized with avidin-FITC 
(Vector Laboratories, Burlingame, CA, USA). Post-hybridization washes 
were performed for directly-labelled (Spectrum Green™) probes. All 
hybridizations were mounted with Vectashield Mounting Medium con-
taining DAPI (Vector Laboratories, Burlingame, CA, USA). On average 
approximately 100 interphase nuclei, with no overlapping nuclei, were 
scored (range 30-200).
Samples were analyzed without prior knowledge of  the exposure 
status. The tissue cores on the TMA slides were analyzed without any 
prior knowledge of  which of  the cores originated from the same tumour.
At the 9q region, copy numbers for each locus were calculated by 
subtracting the locus-specifi c signal counts from the signal count of  
centromere 9 (FISHBright 550-labeled [red], Qbiogene, Illkirch, France 
and Kreatech, Amsterdam, Netherlands). Samples with a locus-minus-
centromere value higher than 0.9 were considered to carry a gain and 
with lower than -0.9, a loss. The frequency of  gains and losses at each 
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locus was compared between the asbestos-exposed and non-exposed 
patients’ tumours.
At the 2p region, a ratio between the signal counts for each locus-
specifi c probe and the signal count for centromere 2 (SpectrumOr-
angeTM-labelled, Vysis Inc./Abbott Molecular Inc., IL, USA) was used to 
calculate the copy numbers. Samples showing a locus-centromere ratio 
of  1.3 or higher were considered to carry a gain and with 0.75 or lower, 
a loss. The frequency of  gains and losses at each locus was compared 
between the asbestos-exposed and non-exposed patients’ tumours. In 
addition, the prevalence of  gains and losses was compared in the 2p21 
and 2p16 regions separately. Differences within histological types were 
tested separately if  the number of  cases was suffi cient to allow statisti-
cal testing.
The locus-specifi c copy numbers were calculated differently for 9q 
and 2p, because of  the frequent trisomy of  chromosome 2 detected 
with the centromere 2 probe. Chromosome 9 mostly showed disomy 
and occasionally monosomy or trisomy, detected with the centromere 
9 probe. Therefore, we chose a more sensitive method for analysing 
locus-specifi c CNA at 2p than was used at 9q. The cutoff  values were 
based on results from normal samples.
3.3.3 Centromere FISH
Centromere FISH probes for chromosomes 2 (SpectrumOrangeTM, Vysis 
Inc), 3 (biotinylated, Oncor, Gaithersburg, MD, USA), 9 (FISHBright, 
Kreatech Diagnostics, Netherlands), 10 and 15 (Spectrum GreenTM- 
and SpectrumAquaTM-labelled Vysis Inc) were used to estimate tumour 
ploidy in 100 tumour samples from both collections (45 fresh-frozen 
and 55 FFPE; 58 asbestos-exposed and 42 non-exposed). The probes 
were hybridized to TMA slides and slides with fresh-frozen samples 
and washed according to the manufacturer’s instructions, respectively, 
at 65 ºC or 73 ºC.
Ploidy for each tumour was assessed by the average of  the signal 
counts from three to fi ve centromere probes. Average signal counts of  
above 2.5 were considered to represent polyploidy.
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3.4 Gene expression microarrays (IV)
RNA from the cell line samples was extracted and purifi ed using Qia-
gen RNeasy kit (Qiagen Inc., Valencia, CA, USA) and the RNA quality 
was measured using Agilent’s BioAnalyzer (Agilent Technologies, Palo 
Alto, CA).
Each sample and one replicate from any time point for each cell line 
were hybridized to Affymetrix Human Genome U133 Plus 2.0 oligo-
nucleotide microarrays (Affymetrix, Santa Clara, CA). Five μg of  high-
quality total RNA was reverse transcribed to cDNA using a Superscript 
Double Stranded cDNA Synthesis kit (Invitrogen, Paisley, UK). The 
cDNA was linearly amplifi ed and in vitro transcription reactions using 
the BioArray high-yield RNA transcript labelling kit (T7; Enzo Life Sci-
ences, Farmingdale, NY) were carried out to produce biotinylated CTP 
and UTP-labelled cRNA. The labelled and fragmented cRNA was then 
hybridized to the Affymetrix microarrays for 16 h at 45ºC in a rotating 
oven (60 rpm). The arrays were washed and stained with streptavidin-
phycoerythrin (SAPE) in a Fluidics station 450 (Affymetrix, 2004), 
and scanned with Affymetrix GeneChip Scanner 3000. The image was 
analyzed using the GeneChip operating software (GCOS; Affymetrix, 
Sacramento, CA) and Comparison Analysis was done according to the 
instructions provided by the manufacturer.
The arrays were scaled to the target value of  100 and absent and 
present calls were identifi ed with Affymetrix Analysis Suite v. 5 (MAS 
5.0). Arrays showing a background of  35-70 and housekeeping control 
genes signal ratios close to 1.0 were included in the data analysis.
Pre-processing of  the hybridization data was performed using RMA 
(Robust Multi-array Average) (Irizarry et al., 2003) with default settings 
(i.e., quantile normalization) in R. AFFX control sets and probe sets lack-
ing GeneID information were excluded from the analyses. In addition, 
probe sets were exluded from the analyses when the “present / marginal / 
absent” expression rating system used in Affymetrix microarray analy-
sis software (Affymetrix, 2004) (here, an open source implementation 
(Gautier et al., 2004) of  the Affymetrix algorithms was used) declared a 
probe set as absent in all microarrays relevant to the experiment. RMA 
pre-processing, designed to enhance the comparability of  expression 
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values between separate arrays, produces a single logarithmic expres-
sion value for each probe set in the Affymetrix arrays. In the case of  
replicates, the mean RMA value was used in the analysis.
BioConductor package ‘hgu133plus2’, version 1.10.0 was used to 
obtain gene and chromosome band assignments (Bioconductor). Only 
unique assignments to properly named chromosome bands were used 
in the analysis.
In order to be able to interpret the large amount of  gene expres-
sion data obtained from these array experiments and place it back into 
its biological sense, three different bioinformatics methods specifi cally 
modifi ed to suit this experiment were performed.
3.4.1 GO analysis
A statistical analysis of  Gene Ontology (GO) annotation terms was 
performed. A method, similar to that described by Breitling et al. (2004) 
was used to identify asbestos exposure-associated biological processes. 
All cell lines were analyzed separately. Each time point was analyzed 
for both under- and overexpressed groups of  genes. Genes were fi rst 
rank-ordered according to their logarithmic fold-change values between 
exposed and corresponding non-exposed samples. In the case of  multiple 
probe sets corresponding to a unique gene (GeneID), the ‘_at’ set with 
the highest overall expression level in the three cell lines was chosen. 
If  no ‘_at’ sets were available, one of  the sets was selected at random. 
The ‘_at’ sets are designed to recognize one unique transcript only. 
Each gene was assigned to a biological process and a hypergeometric 
distribution was used for the statistical evaluation of  enriched terms. Af-
fected biological processes were determined by using the iGA (iterative 
Group Analysis) algorithm by Breitling et al. (2004). For a given gene 
class, iGA computes the minimal class-wise hypergeometric “p-value”. 
The signifi cance of  this statistical indicator was here assessed by com-
paring its value against a distribution of  10 000 random permutations 
of  the data. GO terms with a permuted p-value of  less than 0.01 were 
considered signifi cant.
In addition, the most detailed (with the least genes) biological proc-
esses were detected by ordering the GO terms in branches according to 
their parent-child relationships. It was assumed that truly signifi cantly 
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affected processes should be detected on several levels of  this tree-like 
structure. Therefore, branches with at least three affected terms (p<0.01) 
were identifi ed and the most detailed term containing less than 100 
genes was listed.
Furthermore, in this thesis, the results from this analysis were also 
compared with results from patient samples obtained in a later study (Ru-
osaari et al., 2008a). In that study, a similar GO analysis was performed 
on gene expression data from patient samples. Briefl y, differentially 
regulated pathways (GO terms) were identifi ed in normal and tumour 
tissue of  asbestos-exposed as compared to non-exposed patients. To 
pinpoint the most relevant fi ndings, branches containing at least three 
signifi cant GO terms were identifi ed and the most detailed terms (con-
taining less than 100 genes) were listed. The signifi cant biological proc-
ess terms identifi ed in the GO and cluster (see below) analyses on the 
cell line data were compared with the most relevant biological process 
terms in the patient data. 
3.4.2 Clustering
A differential expression time series for each probe set was formed by 
subtracting the expression values measured in the non-exposed control 
from the values in the corresponding asbestos-exposed sample at each 
time point. Probe sets were excluded from the analysis when none of  the 
time points showed an approximate >1.4-fold (√2) difference between 
the non-exposed and exposed cell samples. Subsequently, genes with 
similar time dependent expression profi les were clustered.
After the pruning procedures, 7 538 (MeT5A), 12 436 (A549), or 
16 640 (BEAS-2B) probe sets remained. Each remaining probe set was 
treated as the sole representative of  a gene. The cluster analysis included 
a total of  19 710 out of  the 54 675 different probe sets on the Affymetrix 
array, in at least one cell line.
The remaining data sets from each cell line were clustered using an 
algorithm specifi cally designed for short time series expression data 
(Ernst et al., 2005; Korpela et al., 2006). However, signifi cant clusters 
were not grouped as in the original paper. Each probe set was assigned 
to one of  50 model profi les during the clustering procedure. Using a 
permutation test, the algorithm labelled some clusters as being statisti-
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cally signifi cant (p<0.05, Bonferroni corrected), based on their expected 
and realized number of  probe sets.
In addition, enriched biological processes (GO) as well as enriched 
chromosomal regions (both referred to as “terms” in the following sec-
tion) for each cluster were listed. The probability of  having at least the 
observed number of  probe sets associated with a given term, assuming 
a random selection of  probe sets, was calculated. All probe sets on the 
microarray (54 675) were used as a reference set. The enrichment of  the 
terms in each gene cluster was evaluated by computing p-values from 
the hypergeometric distribution. 
In this thesis, the enriched GO terms identifi ed in the signifi cant 
clusters of  each cell line were also compared to the results from the GO 
analysis in patient samples (Ruosaari et al., 2008a), as described above 
in Section 3.4.1.
3.4.3 Enriched chromosomal regions
A canonical correlation analysis (CCA)-based method (Hotelling, 1936) 
was performed on the A549 and BEAS-2B cell lines combined. CCA 
identifi es correlations, i.e. shared variations between two data sets. The 
MeT5A cell line was excluded from the analysis due to the scarcity of  
time points in comparison to the other two cell lines. Multiple probe 
sets corresponding to the same gene were treated as in the GO analysis 
described above. Based on the results from CCA the genes were or-
dered according to their contribution to the dependencies of  the two 
data sets, which was measured by the squared sum of  CCA projection 
scores. Finally, enrichment in 307 chromosome bands (Bioconductor) 
was tested. The p-values were evaluated by permutation testing as in 
the GO analysis.
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1. Asbestos-related genetic alterations in 
lung cancer
1.1 Genome-wide copy number alterations (I)
Typical patterns of  alterations for different histological types of  lung 
cancer were identifi ed with cCGH. SCLC showed the highest number 
of  alterations, irrespective of  exposure. A higher number of  CNA 
were detected in the exposed than in the non-exposed group in all 
histological types, except SCC (Table 4). The tumour stage-groups I to 
II and III to IV also showed more CNA in the tumours from exposed 
patients compared to those from non-exposed patients (Table 4). The 
sole specifi c alteration that seemed to differ signifi cantly between the 
asbestos-exposed and the non-exposed groups was a gain at the minimal 
overlapping region 2p23. This gain was present in 57% (8/14 cases) 
of  the exposed and in 14% (2/14 cases) of  the non-exposed patients’ 
tumours (p=0.025). In 7 out of  these 8 exposed cases, the gain affected 
also 2p22 and in 4 cases 2p21. 
All the large and most prominent alterations seen with cCGH were 
also detected by aCGH, which in addition detected some smaller al-
terations, such as a relatively frequent amplifi cation at 12q13.3–14.1 
(Wikman et al., 2005). The aCGH results were, however, not analyzed on 
an individual level, since our goal was to identify differences between the 
asbestos-related and non-related lung tumours. An analysis at the group 
level does not require any a priori knowledge of  the type of  alteration 
in individual cases. Thus, no patient-specifi c alterations were listed. A 
combined statistical analysis on the data revealed 18 regions, in which 
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the DNA copy number between the exposed and non-exposed groups 
differed signifi cantly (Figure 9 and Table 3 in Study I). None of  these 
regions seemed to harbour high-level DNA copy number changes, 
but instead low-level gains or losses. The median size of  the asbestos-
associated regions was 1.74 Mbp. The most signifi cant differences were 
detected in the regions 2p21–p16.3, 5q35.3, 9q33.3–q34.11, 9q34.13–
q34.3, 11p15.5, 14q11.2 and 19p13.1–p13.3 (p<0.005, Table 3 in Study I).
In addition, eleven fragile sites, two of  which were situated at the 
9q region, coincided with the 18 asbestos-associated regions (p=0.08).
Table 4. Median number of CNAs detected in asbestos-exposed and 
non-exposed patients tumours using cCGH.
Number of samples Median number of CNA
Exposed Non-exposed Exposed Non-exposed
Histology
AC 5 6 6 1
SCC 4 4 1,5 10
AC/SCC 1 1 5 4
LCLC 3 2 5 1
SCLC 1 1 23 14
Stage
I–II 8 8 3,5 2
III–IV 6 6 6 2,5
All 14 14 5 2
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1.2 Genetic alterations at 9q (II)
1.2.1 Allelic imbalance
Fifteen microsatellite markers were used to identify allelic imbalance 
(AI) at 9q31.3–34.3 in lung cancer samples from 29 non-exposed and 
23 asbestos-exposed patients. The frequency of  heterozygosity (i.e. 
informativity) for each marker correlated well with the reported degree 
of  heterozygosity.
AI was detected in 27–74% of  the samples, depending on the marker. 
All histological tumour types showed some degree of  AI. Microsatel-
lite instability (MSI) was detected in 47% (7/15) of  the markers of  one 
tumour with SCLC histology from a non-exposed patient. The same 
case had previously been identifi ed to harbour MSI with the colon MSI 
marker BAT-26 and with microsatellite markers at 19p13 (Wikman et 
al., 2007).
A higher frequency of  AI was detected with all markers in the asbes-
tos-exposed (42%–90%) than in the non-exposed (10%-65%) patients´ 
samples. Considering the whole region, 9q31.3–34.3, AI (AI in >25% 
of  the markers) was detected in all (17/17) of  the exposed cases and in 
64% (14/22) of  the non-exposed cases (p=0.005, Fisher’s exact test). 
In addition, a small region at 9q33.1 (base pairs 121021696-121169435) 
was tested separately. This region included the marker showing the most 
signifi cant asbestos-associated AI (TC-repeat, Table 5) compared to 
all the other markers, as well as two adjacent markers (AC-repeat and 
D9S195, Table 5). Signifi cantly more AI (AI in >1 of  at least 2 informa-
tive markers) at this locus was detected in the exposed patients’ tumours 
(73%, 11/15) in comparison to the non-exposed patients’ tumours (21%, 
4/19; p=0.002, X2-test, Figure 10). The different histological types could 
not be tested separately due to the small number of  samples; however a 
similar trend could be seen among all types and especially in AC (AI in 
0% [0/8] of  the non-exposed and 50% [3/6] of  the exposed).
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Figure 10. Allelic imbalance (AI) at 9q33.1 in the tumours of asbestos-
exposed and non-exposed patients. The column denoted AI/n shows the 
number of markers with AI/number of informative markers. Black, AI; white, 
no change; gray, non-informative/no result available; bold, AI in >1 marker.
Exposure Histology 9q33.1 AI/nTCrepeat ACrepeat D9S195
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1.2.2 Copy number alterations
Six BAC probes and a centromere 9 probe were used to analyze CNA 
at 9q32–34.3 with FISH. CNA at the locus were detected in 15–41% 
of  the tumour samples, depending on the probe (losses in 5–27% and 
gains in 7–14%). 
At 9q33.1, losses were more frequent than gains in the three major 
histological types of  NSCLC, i.e. AC, SCC and LCLC. In the other rarer 
NSCLC types and in SCLC, losses and gains could be detected with 
equal frequencies. Thus, we decided to analyze the three major types of  
NSCLC as a group. SCLC and rare histological types were not tested 
separately due to the small number of  samples.
Overall, depending on the probe, CNA at 9q were detected in 14–45% 
of  the asbestos-exposed patients’ tumours and in 15-36% of  the non-
exposed patients’ tumours. Among the NSCLC tumours, signifi cantly 
more frequent CNA at 9q33.1 (RP11–440N22) was detected in the tu-
mours of  asbestos-exposed (41%, 15/37) than in those of  non-exposed 
patients (18%, 6/34; p=0.03, X2-test; Table 5). The same trend could be 
seen among all histological types with the difference being most signifi -
cant among AC, 40% (6/15) in exposed and 6% (1/16) in non-exposed 
(p=0.04, Fisher´s exact test). Similar results were obtained both with 
the fresh-frozen and the FFPE samples when analyzed separately (data 
not shown). A dose-dependent trend could be observed with increas-
ing pulmonary fi bre count of  the patients and CNA at the locus was 
detected in 18% (6/34) of  the tumours from non-exposed patients, in 
35% (8/23) of  the tumours from patients with between 1 and 9.9 mil-
lion fi bres/g and in 50% (7/14) of  the tumours from patients with a 
pulmonary fi bre count of  10 million fi bres/g or more (p=0.03, exact 
Cochran-Armitage trend test, Figure 12a). The trend was also signifi -
cant among the AC tumours: CNA in 6% (1/16) of  the tumours from 
non-exposed patients, in 25% (2/8) of  the tumours from patients with 
1 to 9.9 million fi bres/g and in 57% (4/7) of  the tumours from patients 
with 10 million fi bres/g or more (p=0.01, exact Cochran-Armitage trend 
test, Figure 12b). A similar, but non-signifi cant trend (p=0.10) was seen 
when the SCLC and rare histological types were included in the analysis 
(data not shown).
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1.3 Genetic alterations at 2p (III)
1.3.1 Allelic imbalance
Fourteen microsatellite markers were used to identify AI in 27 lung 
tumours from exposed and non-exposed patients. The heterozygosity 
rates of  the markers correlated well with the reported frequencies. 
AI was detected in 16-61% of  the samples, depending on the marker. 
Microsatellite instability (MSI) at 2p was observed in two ACs (one 
asbestos-related and one non-related) and in one non-asbestos-related 
SCLC. 
With the exception of  one marker all of  the other markers displayed 
an equal or higher frequency of  AI in the asbestos-exposed patients’ 
(18–88%) than in the non-exposed patients’ (0–50%) tumours. At 2p16.3 
(D2S123), AI occurred in 63% (5/8) of  the asbestos-exposed and in 
0% (0/5) of  the non-exposed patients’ tumours (p=0.08, Fisher’s exact 
test). The markers D2S2739 and D2S2251 adjacent to D2S123 at 2p16 
showed similar trends of  asbestos association (Table 6).
Overall, AI was more frequent (AI in >25% of  the markers) in the 
lung tumours of  asbestos-exposed (11/13, 85%) than in those of  non-
exposed patients (4/12, 33%, p=0.02, Fisher’s exact test). In the region 
2p16, which included fi ve markers, the difference was even more sig-
nifi cant, 67% (8/12) of  the exposed and 7% (1/14) of  the non-exposed 
patients tumours showed AI (p=0.003, Fisher’s exact test; Figure 11).
1.3.2 Copy number alterations
Five BAC probes and a centromere 2 FISH probe were used to obtain 
DNA copy numbers at 2p21–p16 in 151 lung tumours from exposed 
and non-exposed patients.
CNA were detected in 16-49% of  the tumours, depending on the 
probe at the 2p region (losses in 1–15% and gains in 7–48%). The probes 
at 2p21 revealed mainly gains (33–48%, depending on the probe), while 
the probes at 2p16 showed losses and gains at an approximately equal 
frequency (losses in 7–15% and gains in 7–14%, depending on the 
probe). Therefore, 2p21 and 2p16 were analyzed separately.
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At 2p16.3 (RP11-703K23) more frequent copy number losses were 
detected in the asbestos-exposed (8/70, 11%) patients’ than in the non-
exposed patients’ (1/64, 2%) tumours (p=0.09, Fisher’s exact test, Table 
6). Furthermore, the prevalence of  at least one copy number loss at 2p16, 
including the probes RP11-703K23, RP11-347F1, and RP11–1114A19 
was signifi cantly higher in asbestos-exposed (20%, 14/70 cases) than 
in non-exposed patients’ tumours (8%, 6/71 cases; p=0.05, χ2 test). A 
borderline signifi cant dose-dependence was seen between the losses and 
the level of  asbestos exposure: 8% (6/71) of  the non-exposed patients’ 
tumours, 19% (9/47) of  the exposed with between 1 and 9.9 million 
fi bres/g and 22% (5/23) of  the exposed with 10 million fi bres/g or more 
showed loss at 2p16 (p=0.07, Figure 13a). Although the groups were 
too small to be statistically evaluated, dose-dependent trends could be 
seen for all histological types separately, except for AC (data not shown). 
Thus, the dose-dependence was tested and found to be signifi cant for 
all non-AC tumours together: 4% (2/50) of  the non-exposed patients’ 
tumours, 15% (5/33) of  the exposed with between 1 and 9.9 million 
fi bres/g and 23% (3/13) of  the exposed with 10 million fi bres/g or 
more showed loss at 2p16 (p=0.03, exact Cochran-Armitage trend test, 
Figure 13b). In addition, the probe at 2p16.2 (RP11-703K23) displayed 
a signifi cant difference in frequency of  loss between the exposed and 
non-exposed groups among non-AC tumours (p=0.03, Fisher’s exact 
test, Table 6).
1.4 Polyploidy (II)
Three to fi ve centromere probes for different chromosomes were used to 
estimate the ploidy level in each individual tumour. Average centromere 
signal counts indicating polyploidy (range 2.5 to 4.9) were detected in 
40% (40/100) of  all tumours. A signifi cant difference in the frequency 
of  polyploidy was detected between asbestos-exposed (48%, 28/58) and 
non-exposed patients’ tumours (29%, 12/42; p<0.05, X2-test). The same 
trend could be seen among all histological types and especially among 
AC, 48% (11/23) in exposed and 20% (3/15) in non-exposed (p=0.08, 
X2-test). Similar results were obtained with both the fresh-frozen and 
the FFPE samples when analyzed separately (data not shown). No dose-
dependent trend could be observed.
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2. Asbestos-related gene expression 
changes in cell lines (IV)
Three different cell lines were exposed to asbestos and the changes in 
gene expression compared to non-exposed controls during different time 
points were studied using microarrays. The large set of  data obtained by 
this type of  experiment was scrutinized in three different ways to profi le 
the expression patterns induced in the cells by the exposure.
In the fi rst analysis (GO analysis) it was possible to detect 351 detailed 
Gene Ontology (GO) terms describing biological processes enriched 
in at least one cell line at any one time point. Each term was associated 
with between one and 99 genes. 
The second analysis clustered genes that showed a similar expression 
profi le during the time series in the asbestos-exposed cells compared 
to the non-exposed cells. The clusters could be ordered according to 
their signifi cance, based on the expected and realized number of  genes 
assigned to each cluster. The analysis revealed 12 signifi cant clusters 
in A549, 16 in BEAS-2B, and 3 in MeT5A. Further interpretation and 
elucidation of  the results focused on the three most signifi cant clusters 
in each cell line. Enrichment analyses for GO terms and chromosomal 
loci were performed for each cluster. The clusters contained between 
1085 and 2403 genes, between 10 and 56 enriched biological processes 
and between 8 and 23 enriched chromosomal loci.
The third analysis (CCA) was designed to identify the dependencies 
between the A549 and the BEAS-2B cell lines. To achieve robust results, 
it was decided to focus on the interpretation of  gene groups rather than 
on individual genes. It was hypothesized that the asbestos effects would 
be spatially localized in the chromosomes. Therefore, it was examined 
whether certain chromosomal regions were enriched in the gene list 
obtained by CCA. These regions could potentially be specifi cally affected 
by asbestos exposure (referred to as asbestos hotspots in the follow-
ing), and be common to the cell lines. The analysis revealed 21 enriched 
chromosomal regions containing between 1 and 71 genes contributing 
to the signifi cant dependencies between the cell lines (p-value<0.03; q-
value<0.38; Table 4 in Study IV). The GO terms associated with each 
gene were also listed in this analysis.
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Although the three analyses were not directly comparable, since 
they focused on different aspects of  the data, it was possible to fi nd 
some similarities that could be considered as being most relevant. 
Furthermore in this thesis, the enriched GO terms in the cluster analysis 
and the GO analysis were compared with the most relevant GO terms 
(biological processes) obtained in a similarly performed GO analysis 
on gene expression data from patient samples (Ruosaari et al., 2008a). 
The most relevant results from the cell line study and the unpublished 
results correlated with patient data are summarized below and in Table 
7. The original complete results can be viewed in more detail in the 
original publication (IV).
2.1 Genes
Two genes, TXNDC (TMX1) and BNIP3L, were identifi ed as highly 
signifi cant in all analysis methods. TXNDC (TMX1) is located at 14q22, 
identifi ed in the CCA results and was represented in a highly signifi cant 
gene cluster of  all three cell lines. In addition, it is one of  the genes 
contributing to the differential expression of  the GO term “positive 
regulation of  transcription, DNA-dependent”, which was downregulated 
in all cell lines after 48h of  asbestos exposure. BNIP3L is located at 
8p21, which was represented in the CCA results. The gene contributed 
to the signifi cant downregulation of  the GO term “negative regulation 
of  survival gene product activity” after 48h of  asbestos exposure in all 
cell lines and was present in highly signifi cant gene clusters of  all three 
cell lines.
2.2 Biological processes
The GO terms at the 1h and 48h time points were compared between 
the cell lines to identify commonly enriched biological processes. As 
described in the Methods Section 3.4.1, the focus was resticted to those 
branches of  the GO tree that contained at least three enriched GO terms 
and listed the most detailed term in the results. No common processes 
were observed after 1h of  exposure, whereas 10 common GO terms 
were identifi ed after 48h (Table 1 of  Study IV). The number of  genes 
belonging to the most detailed process of  the branch ranged from 1 to 85.
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Furthermore, common GO terms were examined in the gene cluster 
and the GO analyses. Nine biological processes were identifi ed to be 
signifi cantly enriched in signifi cant gene clusters of  at least two cell lines 
and in at least two time points of  the GO analysis (Table 2 of  Study IV). 
The biological processes “positive regulation of  transcription, DNA-
dependent” and “negative regulation of  survival gene product activity”, 
observed in the cluster and GO analyses, were also associated with genes 
in the regions of  the CCA.
In the study on patient samples, eighteen biological processes were 
found to be the most relevant, when searching for branches with at 
least three signifi cant GO terms differing between asbestos-exposed 
and non-exposed patients’ tumour and normal tissue (Ruosaari et al., 
2008a). Ten of  the 18 terms were also signifi cant in the GO or cluster 
analysis of  at least one cell line (Table 7). One of  the terms, “sensory 
perception of  smell”, was also found to be commonly up-regulated in all 
cell lines after 48h of  exposure. The other terms belonged to branches 
describing ion transportation (2 terms), G-protein signalling (4 terms), 
ubiquitination (1 term), tRNA metabolism (1 term) and humoral im-
mune response (1 term).
2.3 Enriched chromosomal regions
The representation of  the previously identifi ed chromosomal regions 
affected by asbestos-related CNA in lung tumours (I), were examined 
in the results of  the cell line experiment. In the most signifi cant gene 
cluster of  A549 (cluster 5) nine of  the 18 previously identifi ed asbestos-
associated chromosomal regions were enriched, i.e. 11q13, 19p13, 9q34, 
16p13, 1p36, 17p13, 5q35, 3p21, and 22q13 (p<0.01). In addition, cluster 
2 of  A549 contained enrichment of  genes in 5 regions corresponding to 
the asbestos-associated regions in lung cancer. The less signifi cant gene 
clusters 3, 7, and 13 in BEAS-2B contained enrichment of  genes in 3 
to 5 regions and cluster 2 in MeT5A contained enrichment of  genes in 
5 regions corresponding to the asbestos-associated regions. The most 
frequently enriched regions were 19p13, 3p21, 11q13 and 9q34 in all 
signifi cant clusters of  all three cell lines.
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Furthermore, one of  the most signifi cant regions showing differen-
tial copy number changes between the lung tumours of  exposed and 
non-exposed patients was 2p21–16.3. In the cluster analysis it was noted 
that probe sets located at 2p were substantially enriched in the highly 
signifi cant gene clusters 9 of  A549 (p=0.00032) and 5 of  BEAS-2B 
(p=0.000114). Notably the specifi c region 2p21 was enriched in the 
second most signifi cant cluster (1) of  A549 (p=0.0039). In addition, the 
most signifi cant region in the enrichment analysis of  the CCA results 
was 2p22.
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1. Genomic alterations in asbestos-related 
lung cancer
The biopersistant asbestos fi bres can be present in the lungs for dec-
ades and may, during that time, cause several molecular changes in the 
surrounding cells. In vitro experiments have shown that the most typical 
asbestos-induced DNA alterations are losses and breaks (Huang et al., 
1978; Valerio et al., 1980; Hei et al., 1992; Hei et al., 1995; Pelin et al., 
1995; Lohani et al., 2002; Xu et al., 2007; Msiska et al., 2009). During 
the last decade, genome wide analysis methods have proven to be the 
most effi cient in analyzing complex tumours such as lung cancer. Here, 
by using whole genome aCGH and matched groups of  tumour mate-
rial from asbestos-exposed and non-exposed lung cancer patients, it 
was possible to identify a set of  chromosomal regions differing in copy 
number between these two groups. Eighteen regions were identifi ed 
to be affected by differential CNA in tumours from asbestos-exposed 
patients as compared to tumours from non-exposed patients and 13 
of  the regions seemed to be affected by losses in the exposed group 
(I, Figure 9). The seven statistically most signifi cant regions identifi ed 
were 2p21-p16.3, 5q35.3, 9q33.3-34.11, 9q34.13-34.3, 11p15.5, 14q11.2 
and 19p13.1-p13.3.
The aCGH study was performed using reference samples from only 
two healthy individuals, which may have caused biased results due to 
the recently discovered polymorphic CNVs. There is a possibility that a 
duplication/deletion in the reference DNA is interpreted as a loss/gain 
in the tumour DNA. This is, however, unlikely in this study considering 
the size of  the identifi ed asbestos-related CNAs. The average size of  
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CNVs has been reported to be within the range of  several kilobases 
(Redon et al., 2006), while the CNA identifi ed here were all in the range 
of  1 megabase or more (Table 3 in Study I). In addition, the choice of  
using a combined statistical analysis, where the array results from the two 
tumour groups were compared to each other at the group level, should 
eliminate the risk of  detecting false positive CNAs due to CNVs, since 
the same references were used in both groups. The group level analysis 
may not, however, fully compensate for the noise present in the arrays 
caused by for example normal cell contamination. Therefore, there is a 
slight possibility that, for instance a gain in one of  the tumour groups 
could be interpreted as a loss in the other group. Nonetheless, one of  the 
regions which seemed to be lost in the asbestos-related group, 3p21, has 
previously been reported to be signifi cantly more frequently affected by 
LOH in the tumours from asbestos-exposed patients compared to those 
from non-exposed patients (Marsit et al., 2004). Furthermore, the CNAs 
at 19p13, which seemed to be both lost in the asbestos-related group 
and gained in the non-related group, were later verifi ed with FISH in a 
larger study population. (Ruosaari et al., 2008b.) These results indicate 
that at least in these regions the original array results were correctly in-
terpreted. Previous in vitro experiments have shown that asbestos fi bres 
are mainly involved in causing breaks in chromosomes 1 and 9 (Dopp 
et al., 1998; Lohani et al., 2002) as well as loss of  one or both copies of  
chromosome 5 and monosomy of  chromosome 19 (Suzuki et al., 2001). 
Here, two asbestos-related CNAs were identifi ed in chromosome 1, three 
in chromosome 9 and one each in chromosomes 5 and 19. Finally, a 
recent aCGH study on mesothelioma, which is tightly linked to asbestos 
exposure, identifi ed frequent CNA in 17 chromosomal regions with 
fi ve of  them (1p36.22-36.23, 3p21.31, 9q34.11, 17p13.11 and 19p13.2) 
corresponding to those identifi ed here in asbestos-related lung cancer 
(Ivanov et al., 2009).
Another type of  microarrays was used to study gene expression 
changes in asbestos-exposed cell lines and 21 chromosomal regions 
enriched with genes that contributed to the common asbestos-related 
responses in two exposed cell lines were identifi ed (Table 4 in Study 
IV). It can be postulated that these regions may be especially prone to 
asbestos-induced DNA damage, i.e. asbestos hotspots, which conse-
quently affects the expression of  the genes in those regions. Interest-
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ingly, the most signifi cant region was 2p22, which is close to the 2p 
region affected by differential CNA in asbestos-exposed compared to 
non-exposed patients’ tumours.
Here, the asbestos-related regions at 2p and 9q were chosen for fur-
ther analysis by other methods and in larger study populations (II and III).
1.1 Allelic imbalance and copy number alterations at 
9q (II)
The long arm of  chromosome 9 has been characterized with losses in 
around 15%, gains in about 7% and AI in 40-60% of  lung cancers (Baudis 
et al., 2001; Beau-Faller et al., 2003; Girard et al., 2000; Merlo et al., 1994). 
These frequencies correspond well to our results. In addition, it was 
possible to correlate the results with the amount of  asbestos exposure 
of  the patients. The whole 9q31.3-34.3 region harboured >25% AI in 
all of  the exposed and in 64% of  the non-exposed patients’ samples. In 
particular, 9q33.1 was signifi cantly more frequently affected by AI in the 
exposed group (73% versus 21%; Table 5 and Figure 10). Although, it 
is important to notice that the percentage of  non-informative results at 
9q33.1 was higher in the non-exposed group than in the exposed group 
(Figure 10), which may affect the signifi cance of  the results. However, 
with FISH it was also possible to detect more frequent CNA at 9q33.1 
in the asbestos-exposed and these alterations showed a dose-dependent 
association in NSCLC (Figure 12a). Additionally, it was noted that the 
correlation of  CNA at 9q33.1 with asbestos exposure was particularly 
signifi cant among tumours with AC histology compared to other histo-
logical types, although the number of  samples was small (Figure 12b). 
The region 9q33.1 harbours a tumour suppressor gene, deleted in 
bladder cancer 1 (DBC1), which has been found to be down regulated 
by several mechanisms in many types of  cancer (Gao et al., 2004; Beetz 
et al., 2005; Gronbaek et al., 2008). The gene has been shown to inhibit 
cell proliferation by negative regulation of  the G1/S transition of  the cell 
cycle (Nishiyama et al., 2001). In a previous gene expression study on 
the same patient samples as the ones used here in the aCGH study (I), 
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Figure 12. Frequency of CNA at 9q33.1. A) The major histologic tumour types 
of NSCLC (i.e. AC, SCC and LCLC, p=0.03) and B) AC tumours (B, p=0.01) from 
asbestos-exposed (>10 and 1–9.9 million fibres/g) and non-exposed (0–0.5 million 
fibres/g) patients. The number of samples with CNA/number of all samples is shown 
above each column. 
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low expression of  DBC1 was detected in both normal lung and tumour 
samples and there was no signifi cant difference between the exposed and 
non-exposed groups (Wikman et al., 2007). The gene has been found 
to be frequently methylated and down-regulated in NSCLC as well as 
in adjacent normal tissue of  smokers (Izumi et al., 2005). Thus, it is 
possible that DBC1 is central to the development or progress of  both 
asbestos-related and non-related lung cancer, but that the mechanism of  
down-regulation may be different in the two groups. The combination 
of  smoking and asbestos exposure may increase the probability of  a cell 
acquiring CNA in one allele and methylation in the other, elevating the 
risk of  cancer according to Knudson’s two-hit hypothesis (Knudson, 
1971). A similar difference between asbestos-related and non-related 
lung cancer was recently reported for the gene P16/CDKN2A. LOH 
and homozygous deletion of  this gene were found to be associated with 
asbestos exposure, while promoter hypermethylation was correlated 
with heavy smoking in lung cancer. Consequently, the gene was down-
regulated in the tumours of  both exposure groups (Andujar et al., 2010). 
CNA at 9q has been reported in 10–15% of  mesotheliomas 
(Björkqvist et al., 1998b; Lindholm et al., 2007; Taniguchi et al., 2007). 
Interestingly, two aCGH studies on mesothelioma discovered 6 of  43 
cases with CNA at 9q and 3 of  those cases harboured losses initiating at 
9q33.1, indicating a potential breakpoint hotspot for asbestos-induced 
DNA damage (Lindholm et al., 2007; Taniguchi et al., 2007). It is also 
worth mentioning that the gene TNC (HXB), which resides at 9q33.1 
and is involved in wound healing has been found to be down-regulated 
in mesothelioma cell lines (Kettunen et al., 2001).
1.2 Allelic imbalance and loss at 2p (III)
The short arm of  chromosome 2 has been reported to be affected by 
gains in 16.5–50% depending on the study, by losses in approximately 
5% (32% in SCLC) and by AI in 25–45% of  lung tumours (Balsara et 
al., 1997; Dehan et al., 2007; Garnis et al., 2006; Michelland et al., 1999; 
Otsuka et al., 1996; Petersen et al., 1997; Shen et al., 2009; Weir et al., 2007; 
Wong et al., 2002; Xinarianos et al., 2000; Björkqvist et al., 1998b; Yan 
et al., 2005; Björkqvist et al., 1998a). Similar frequencies were detected 
in our samples. Additionally, it was also possible to detect a signifi cant 
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asbestos association with both copy number loss (20% vs 8% in ex-
posed and non-exposed patients’ tumours, respectively) and AI (67% 
vs 7%, Figure 11) at 2p16. In the AI analysis, the percentage of  non-
informative results at the 2p16 region was higher among the nonexposed 
cases (Figure 11), similarly as at the 9q33.1 region, which may affect the 
signifi cance of  the result. Nevertheless, a dose-dependent association 
was also observed between FISH-detected loss at 2p16 and asbestos 
exposure and the trend was especially signifi cant among tumours with 
non-AC histological type (Figure 13). In the genome wide aCGH study 
(I) an association was detected between fragile sites and the asbestos-
associated CNAs. The aphidicolin-sensitive fragile site, FRA2D is located 
at 2p16.2 adjacent to the microsatellite marker D2S123 (Schwartz et al., 
2006), which in comparison with the other markers showed the most 
signifi cant difference in AI between the exposed and non-exposed 
groups (63% and 0%, respectively, Table 6). Thus, the fragile site may be 
involed in the mechanism of  asbestos-induced damage in this region. It 
is worth mentioning that the overall frequency of  AI at D2S123 (38%) 
correlated well with a previously reported frequency in lung cancer 
(30%, Wong et al., 2002). 
Copy number loss as well as LOH and UPD at 2p16 has been detected 
in other types of  cancer such as ovarian carcinoma, meningioma and 
hereditary non-polyposis colorectal cancer (Lucci-Cordisco et al., 2005; 
Krupp et al., 2008; Plisiecka-Halasa et al., 2008). The cancer syndrome 
Carney complex (CNC), which is associated with multiple neoplasms, 
has also been characterized with gains and losses at 2p21-p16 (Matya-
khina et al., 2003). Furthermore, the precursor of  miR-216, located at 
2p16.1, has been found to be down-regulated in lung cancer (Yanaihara 
et al., 2006). It is intriguing to speculate that miR-216 is involved in the 
tumorigenesis of  both asbestos-related and non-related lung cancer, but 
once again by separate mechanisms, similarly as the previously mentioned 
p16/CDKN2A gene.
In the cell line experiment (IV), signifi cantly enriched chromosomal 
regions were also tested for in the most signifi cant gene clusters, i.e. 
those clusters that contained more similarly expressed genes than ex-
pected. Consequently, in addition to identifying an asbestos hotspot 
at 2p22, genes located at 2p were found to be substantially enriched 
in highly signifi cant gene clusters of  the two epithelial cell lines, A549 
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A)
B)
Figure 13. Frequency of loss at 2p16. A) All histological tumour types (p=0.07) and 
B) non-AC tumours (p=0.03) from asbestos-exposed (>10 and 1–9.9 million fibres/g) 
and non-exposed (0-0.5 million fibres/g) patients. The number of samples with loss/
number of all samples is shown above each column.
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and BEAS-2B. These results could indicate that either alterations at 2p 
and consequently changes in the expression of  the genes in the region 
are specifi cally involved in the asbestos-related cellular responses or vice 
versa. I.e. asbestos-related gene expression changes in the region may 
sensitize it to genomic alterations, while it is in an open conformation, 
allowing transcription (Obe et al., 2002).
1.3 Chromosomal regions enriched with asbestos 
exposure response genes (IV)
Many of  the regions identifi ed in the cell line experiment as potential 
asbestos hotspot regions correspond to regions frequently found to be 
affected by CNA in mesothelioma, i.e. 4q, 6q, 8p, 8q22-23, 9p13, 14q 
and 15q (Kivipensas et al., 1996; Lindholm et al., 2007; Baudis, 2009). In 
particular, two regions are worth mentioning, namely 8p21 and 14q22. 
Both regions contain one interesting gene each. Single genes are usually 
of  less interest in a genome wide analysis such as this one, since signifi -
cant differences in the expression of  single genes are expected to arise 
at random, due to the large amount of  data. Nevertheless, these two 
may be mentioned due to their high signifi cance in all analyses on all cell 
lines and because of  their asbestos-related functions and relationships 
with previously identifi ed asbestos-associated genes. 
The chromosomal region 8p21 harbours the gene encoding for a 
BCL2/adenovirus E1B 19kD-interacting protein (BNIP3L). BNIP3L 
is a potential tumour suppressor, associated with hypoxia-induced ap-
optosis of  epithelial cells (Krick et al., 2005). The gene was involved in 
the down-regulation of  the biological process “negative regulation of  
survival gene product activity”, i.e. a proapoptotic process, in all cell 
lines at 48h of  exposure (Table 1 in Study IV). Thus, loss of  the gene 
may result in apoptotic bypass.
Region 14q22 harbours the thioredoxin domain containing gene 
(TXNDC also known as TMX1). TXNDC was found to contribute to 
the down-regulation of  the biological process “DNA-dependent positive 
regulation of  transcription” in all cell lines at 48h exposure (Table 1 in 
Study IV). Thioredoxin (TXN) is involved in the DNA-binding activity 
of  NF-κB, which has been shown to be up-regulated by asbestos expo-
sure (Shukla et al., 2003b). TXNDC has been found to have TXN-like 
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functions and may in addition be involved in relieving endoplasmic re-
ticulum (ER) stress, such as that induced by asbestos exposure (Matsuo 
et al., 2001; Nozaki et al., 2001). Thus, loss of  the gene may contribute 
to inability of  the cell to protect itself  against ER stress.
1.4 Polyploidy and aneuploidy
The ploidy level of  the tumours was analyzed using fi ve centromere 
FISH probes and signifi cantly more frequent polyploid tumours were 
detected among the asbestos-exposed (48%) than the non-exposed 
(29%) patients. The difference was particularly signifi cant among tu-
mours with AC histology compared to other histological types (48% vs 
20% in exposed and non-exposed, respectively). Asbestos is known to 
cause chromosome missegregation and the fi bres have been shown to 
induce polyploidy by sterically blocking cytokinesis in vitro (Jensen et al., 
1996; Jaurand, 1997). Polyploidy has been suggested to act as a catalyst 
to promote further CIN and aneuploidy (Holland et al., 2009), which 
may explain the fi nding that asbestos-exposed patients’ tumours show 
a larger number of  alterations as detected with cCGH (Table 4). How-
ever, it is not certain whether polyploidy leads to aneuploidy in cancers 
or vice versa. In vitro, asbestos seems to be able to cause both aneuploidy 
and polyploidy (Jensen et al., 1996; Suzuki et al., 2001). Thus, the chro-
mosomal alterations detected in asbestos-related lung cancer need not 
only be nonspecifi c results of  polyploidy-directed CIN, but may also be 
induced in specifi c regions by asbestos fi bres before the development 
of  polyploidy, which has been indicated by the fi ndings at 2p and 9q in 
this thesis, and at 19p13 (Wikman et al., 2007; Ruosaari et al., 2008b). 
Polyploidy may confound the analysis of  CNA in specifi c chromo-
somal regions, since low level alterations may not be detected as easily 
by CGH as in diploid genomes. This may explain the diffi culty over the 
years in identifying specifi c asbestos-associated CNA. Increased ploidy 
levels and thus increased overall gene copy numbers could contribute 
to the over-expression of  many genes (reviewed in Petersen et al., 
2009). However, losses may not affect the expression of  genes if  the 
genome is polyploid and an extra copy compensates for the expression 
of  genes in a region showing a one-copy loss. This may explain why 
asbestos-associated increased expression of  the genes in the 2p region 
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was detected in a study examining the gene expression in the same 
patients as in the aCGH study (I; Wikman et al., 2007) and at the same 
time asbestos-associated copy number losses were detected here (III). 
The losses were defi ned by calculating a ratio between the locus specifi c 
probe and the centromere of  chromosome 2, which often implied tri-
somy or tetrasomy of  the chromosome. Thus, one-copy losses would 
not affect the possible up-regulation of  the genes in that region, caused 
by the polyploidy or aneuploidy. 
Due to these complex alteration patterns, asbestos-related CNA 
may not always cause a differential expression profi le compared to 
non-asbestos-related lung cancer, which is also demonstrated by the 
previously mentioned fi ndings on the P16/CDKN2A and FHIT genes. 
These genes are frequently down-regulated in lung cancer, but by dif-
ferent mechanisms in those that are asbestos-related, than in those 
that are not (Pylkkänen et al., 2002a; Andujar et al., 2010; Nelson et al., 
1998). Instead the correlations are simply biomarkers of  the exposure 
and could, regardless of  their biological effects, be useful in identifying 
these tumours among lung cancers without asbestos association.
2. Dysregulated biological processes in 
asbestos-related lung cancer
Several biological processes (GO terms) that were differentially regu-
lated in asbestos-exposed cell lines compared to non-treated cells were 
identifi ed. Many of  those processes are probably due to the triggering 
of  various universal cellular responses to a toxic substance. However, 
by using three different cell lines it was anticipated that it would be pos-
sible to pinpoint the specifi c asbestos-related changes and to be able 
to overlook the cell-type or malignancy-associated changes. Indeed, 
the number of  shared differentially expressed processes increased with 
exposure time, indicating that the response to asbestos exposure oc-
curs through the same pathways in all three cell lines. However, with 
in vitro experiments, one can naturally never precisely refl ect the actual 
conditions and mechanims in vivo. Therefore, in this thesis, the complete 
results from the cell line experiment were correlated with those of  a 
similar study performed later on normal and tumour samples from lung 
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cancer patients with and without past asbestos exposure (Ruosaari et 
al., 2008a). The main aim of  this thesis has been to identify asbestos-
related alterations in lung cancer and therefore the discussion here will 
focus on the processes found to correlate between the cell lines and the 
patient samples.
Ten biological processes were found to correlate between at least 
one of  the cell lines and the patient samples (Table 7). Most of  them 
were different from those found in common between the three cell 
lines themselves. This was to be expected since the differentially regu-
lated processes found in the tumours of  asbestos-exposed patients are 
anticipated to be associated with cancer, while those discovered in the 
cell lines are more likely to be early asbestos-related changes not yet 
involved in the carcinogenic processes. One should keep in mind that 
the development of  clinical cancer associated with asbestos exposure 
appears decades after the initial exposure. The processes found in com-
mon between the two studies could be hypothesized to be related to the 
very early carcinogenic effects induced by asbestos exposure. 
Many of  the processes that correlated between the three cell lines 
at 48h have previously been reported to be asbestos-related, based on 
other types of  in vitro experiments, i.e. NF-κB, MAPK and mitochondrial 
pathways (reviewed in Shukla et al., 2003b; Kamp, 2009). These pathways 
were not found to be signifi cantly dysregulated in the patient samples. 
However, another of  the processes shared by the three cell lines at 48h, 
“sensory perception of  smell” (Table 1 in Study IV), was also found to 
be highly signifi cant in the asbestos-exposed patients’ samples. It was 
the only up-regulated pathway detected in all three cell lines at 48h as 
well as at other time-points of  all cell lines and it was also up-regulated 
in both the tumour and normal samples of  the asbestos-exposed pa-
tients. This fi nding was slightly surprising, but the signifi cance of  its 
discovery was strengthened by the dysregulation of  related processes in 
either the cell lines or the patient samples, namely “sensory perception 
of  sound”, “-taste” and “-light” (Table 7, Figure 14). Interestingly, the 
majority of  the genes involved in the perception of  smell and taste are 
those encoding for G-protein coupled olfactory and taste receptors. 
This could mean that the dysregulation of  G-protein signalling, which 
was also highly represented in the list of  processes found in both cell 
lines and patient samples (Table 7), may affect the regulation of  these 
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receptors. G-proteins have been proposed to be involved in the respira-
tory burst (release of  ROS) caused by asbestos (Elferink et al., 1988). 
Furthermore, the genes implicated in the sensory perception of  smell 
could be involved in other yet unidentifi ed processes. In fact, prostate 
cancer has been characterized with the over-expression of  an olfactory 
receptor, PSGR (Xu et al., 2000). It is also worth mentioning that three 
of  the asbestos-related CNA regions identifi ed in the aCGH study (I; 
16p13.3, 17p13.3 and 19p13.3) contain clusters of  olfactory receptors 
contributing to the up-regulation of  the “sensory perception of  smell” 
in the asbestos-exposed cell lines.
Another process dysregulated in all three cell lines at 48h, i.e. “pre-
nylated protein catabolic process” (Table 1 in Study IV), was closely 
related to a process found in the patient samples. It belongs to the 
same parent process (“modifi cation-dependent protein catabolism”) 
as “ubiquitin-dependent protein catabolic process”, which was down-
regulated in the asbestos-exposed patients’ samples (Table 7). Protein 
ubiquitination regulates various key cellular events, such as DNA repair, 
cell cycle and apoptosis and the dysregulation of  this process has been 
linked to mesothelioma (Borczuk et al., 2007). Interestingly, ubiquitination 
is also involved in DNA damage-activated NF-κB, which as previously 
mentioned is known to be up-regulated by asbestos exposure (Shukla 
et al., 2003b; Skaug et al., 2009). In addition to the process found in 
common between the cell lines and the patient data, six other processes 
related to ubiquitination were also detected in at least one of  the cell lines 
or patient samples (Table 7). The processes were all down-regulated in 
both patient samples and cell lines, except for “negative regulation of  
protein ubiquitination”, which concordantly showed up-regulation. The 
expression and protein levels of  the ubiquitin-activating enzymes, UBA1 
and UBA7, involved in the early stages of  protein ubiquitination, were 
further investigated in the study on patient samples, but neither showed 
any differences between asbestos-exposed and non-exposed (Ruosaari 
et al., 2008a). However, several hundreds of  enzymes are involved in 
the process and the role of  protein ubiquitination in asbestos-related 
carcinogenesis cannot be ruled out, based on these results. Indeed, the re-
gion 2p16, which was found to harbour asbestos-associated AI and copy 
number losses (III) contains two genes (ASB3 and RPS27A) involved 
in protein ubiquitination as well as the previously mentioned miR-216, 
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which has been predicted to target the ubiquitin-conjugating enzyme 
UBE2V2 (Kirschner et al., 2000; Chung et al., 2005; Lewis et al., 2005).
Finally, the biological process of  ion transport was also highly repre-
sented in both the cell lines and the patient samples (Table 7). Asbestos 
could be linked to the up-regulation of  ion channels through ROS, which 
has been shown to trigger the opening of  mitochondrial channels and 
mitochondrial depolarization. Indeed, asbestos has been reported to 
cause a slow and sustained increase in intracellular Ca2+ levels and there 
is some evidence to suggest that the disruption of  intracellular Ca2+ 
levels could, together with ROS, be involved in the asbestos-induced 
DNA strand breaks (reviewed in Shukla et al., 2003b). Dysregulation of  
ion channels has been proposed to have a role in tumourigenesis and 
tumour progression (reviewed in Ruosaari et al., 2008a). 
Other common processes between the GO analyses in the cell lines 
and the patient samples were involved in tRNA metabolism and humoral 
immune response. Both have been implicated in cancer (Tan et al., 2007; 
Park et al., 2008).
Figure 14. Gene Ontology network. The network illustrates the branch 
leading to the biological process “sensory perception of smell” (red box) 
found to be commonly up-regulated in asbestos-exposed cell lines and 
samples from asbestos-exposed lung cancer patients. Terms represented 
either in the cell lines, patient samples or both are marked as described in 
the figure. The figure has been generated using the AmiGO visualization 
tool (Carbon et al., 2009).
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CONCLUSIONS AND FUTURE 
PROSPECTS
Many studies have attempted to explain the extremely high risk of  lung 
cancer among smoking asbestos workers. Nevertheless, none of  them 
have led to truly effi cient screening methods that could reduce mortality 
even though the risk groups are very well known, in contrast to many 
other types of  cancer risk groups. Furthermore, there are no molecular 
markers clinically available for identifying asbestos-related lung cancer 
even though asbestos is well known to be able to evoke alterations in 
the DNA, one of  the hallmarks of  cancer initiation and progression 
(Hanahan and Weinberg, 2000). Around ten years ago, it was estimated 
that past asbestos exposures in Western Europe alone will be responsible 
for at least a quarter of  a million deaths from lung cancer and an equal 
amount of  deaths from mesothelioma over the next 35 years (reviewed 
in LaDou, 2004). Currently, clinical identifi cation of  asbestos-related 
lung cancer relies on occupational history and pulmonary asbestos fi bre 
counts and thus, diagnosis would greatly benefi t from the identifi cation 
of  a specifi c molecular marker (Kamp, 2009).
In this thesis, asbestos-related lung cancer was characterized at a mo-
lecular level in an attempt to pinpoint specifi c asbestos-related alterations 
that differ from lung cancer in patients without this type of  exposure. 
Specifi c chromosomal alterations were identifi ed in 18 regions (I) and 
the alterations in two of  the regions, 2p16 and 9q33.1, were validated and 
characterized in detail (II and III). It is believed that a combination of  
several asbestos-associated molecular changes, such as CNA, could rep-
resent a feasible method for differentiating asbestos-related lung cancers 
from those that are not related to asbestos exposure. Here, signifi cant 
differences in the frequency of  AI and CNA at 2p16 and 9q33.1 were 
found between the tumours of  exposed and non-exposed patients. In 
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addition, the frequency of  polyploidy was signifi cantly higher among 
the tumours of  asbestos-exposed patients. At 9q33.1 the differences 
were especially noteworthy among tumours with AC histology (Figure 
12), while 2p16 exhibited the most considerable differences among the 
tumours with non-AC histology (Figure 13). Thus, in combination the 
alterations at these two regions and previously identifi ed alterations at 
19p13 (Ruosaari et al., 2008b), as well as polyploidy may be useful in a 
test identifying asbestos-related lung cancer irrespective of  histological 
type. Finally, we were also able to experimentally identify changes in 
the expression of  genes in specifi c pathways and chromsomal regions 
that correlated with fi ndings in patient samples, thus validating them 
for further studies (IV).
Some future prospects include (i) validating the asbestos-related chro-
mosomal alterations in combination and in a large study population, (ii) 
performing transcription factor binding site analyses on the gene expres-
sion alterations in patient samples and asbestos-exposed cell lines, (iii) 
profi ling the miRNAome in asbestos-related lung cancer, (iv) genome 
wide association studies of  CNVs associated with asbestos-related lung 
cancer and (v) functional studies based on the most relevant fi ndings.
Transcription factor binding site analyses on gene expression data can 
be used to identify dysregulated transcription factors that consequently 
cause the dysregulation of  their target genes (Yap et al., 2005). This kind 
of  analysis could be performed on a group of  genes showing similar 
expression e.g. during a time series experiment, such as the gene clusters 
generated here in the experiment on asbestos-exposed cell lines (IV).
MiRNAs are rapidly becoming an attractive method for profi ling 
cancers. The miRNAome has proved to be more effi cient in distinguish-
ing between tumour histology, classifying undifferentiated tumours and 
predicting patient outcome, than traditional gene expression profi ling 
of  mRNAs. The majority of, if  not all, cellular processes are likely to 
be regulated by miRNAs and changes in the expression of  these genes 
are a hallmark of  several diseases, including cancer. During the past few 
years several tumour suppressive and oncogenic miRNAs have been 
identifi ed (reviewed in Croce, 2009). Profi ling of  the miRNAome in 
asbestos-related lung cancer would greatly add to the understanding of  
the molecular alterations in this type of  cancer.
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CNVs represent a recently discovered type of  human genetic vari-
ation, i.e. the occurrence of  missing or additional segments of  DNA 
which have been found in two or more genomes of  healthy individuals. 
CNVs are likely to play an important role in the susceptibility of  cancers 
and may interfere with the analysis of  tumour specifi c somatic CNAs. 
During the past few years much attention has been paid to human genetic 
variation, especially CNVs and there are several large ongoing projects 
to map these variations (reviewed in Dear, 2009). It would be tempting 
to perform genome wide association studies of  CNVs associated with 
asbestos-related lung cancer.
Finally, the identifi ed putative biomarkers of  asbestos-related lung 
cancer need to be verifi ed in larger sets of  samples and their biological 
roles in asbestos-related lung carcinogenesis should be clarifi ed using 
functional experiments. Novel high-throughput methods, such as the 
next-generation sequencing (NGS) techniques (reviewed in Metzker, 
2010) could also be a next step in gathering a better understanding of  
the chromosomal alterations and their effects involved in asbestos-
related lung cancer.
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Asbestos is still a serious problem all around the world, even 
though the devastating health effects of breathing in the 
microscopically tiny mineral fibres have been known for over a 
century. Asbestos exposure causes a variety of severe pulmonary 
diseases and unfortunately due to the long latency period 
between exposure and development of disease, this epidemic will 
continue, even in countries where asbestos use has been banned 
for many years.
Asbestos-related lung cancer is one of the most common types 
of occupational cancer. It is clinically indistinguishable from lung 
cancer in patients with no known history of asbestos exposure 
and the treatment is the same for both etiologic types. Never-
theless, the molecular basis may be different and diagnosis as 
well as prognosis and treatment strategies may benefit from the 
identification of specific asbestos-related molecular alterations. In 
addition, these kinds of molecular correlates could be of impor-
tance in resolving some of the medico-legal issues arising from 
occupational diseases.
This study sheds light on the molecular alterations related to 
asbestos exposure in lung cancer and may point the way for the 
development of molecular-based clinical methods for asbestos-
related lung cancer. 
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